DEF 14A

 

 

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

SCHEDULE 14A

Proxy Statement Pursuant to Section 14(a) of the Securities

Exchange Act of 1934 (Amendment No. )

Filed by the Registrant ☒

 

Filed by a Party other than the Registrant

 

Check the appropriate box:

 

☐ Preliminary Proxy Statement

 

Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2))

 

Definitive Proxy Statement

 

Definitive Additional Materials

 

Soliciting Material Pursuant to §240.14a-12

 

EyePoint Pharmaceuticals, Inc.

(Name of Registrant as Specified In Its Charter)

 

(Name of Person(s) Filing Proxy Statement, if other than the Registrant)

 

Payment of Filing Fee (Check all boxes that apply):

 

No fee required

 

Fee paid previously with preliminary materials

 

Fee computed on table in exhibit required by Item 25(b) per Exchange Act Rules 14a-6(i)(1) and 0-11

 

 

 

 

 

 

 

 

 

 

 

 

 


 

 

https://cdn.kscope.io/bfecb590142cdff561e6cf23de2272da-img83600834_0.jpg 

 

 

 

 

 

480 Pleasant Street, Suite C400

Watertown, MA 02472

United States

 

 

 

 

 

April 26, 2024

To Our Stockholders,

2023 was an exceptional year for EyePoint as we executed on our mission to bring innovative, life-changing therapeutics to patients living with serious retinal diseases. We completed our transformation into a clinical-stage biopharmaceutical company with the out-license of the YUTIQ® franchise, and now we are focused on advancing and expanding our pipeline of innovative sustained-delivery treatments to provide a brighter future for those at risk of losing their sight.

 

 

We are focused on advancing and expanding our pipeline of innovative sustained-delivery treatments to provide a brighter future for those at risk of losing their sight.

 

 

 

EyePoint’s bioerodible Durasert E™ drug delivery technology provides a best-in-class sustained release intravitreal insert for treating serious retinal diseases. This technology enables a constant, sustained drug release known as zero order kinetics. We have built a potential multi-billion-dollar pipeline around this innovative drug delivery technology.

In 2023, we made great progress with our lead pipeline program, EYP-1901 (DURAVYU™), an investigational sustained release product that consists of vorolanib, a selective and patent-protected tyrosine kinase inhibitor, formulated in Durasert E™. During the year, we continued our record of strong execution and completed enrollment in two Phase 2 clinical trials in wet age-related macular degeneration (wAMD) and non-proliferative diabetic retinopathy (NPDR). In December 2023, we reported positive topline efficacy and safety data from our Phase 2 DAVIO 2 clinical trial in wAMD, achieving all primary and secondary endpoints

We believe these strong results underscore the potential of DURAVYU (vorolanib intravitreal insert) to be a paradigm-altering treatment for patients suffering from VEGF-mediated retinal diseases. Looking ahead, we expect to report topline data for the Phase 2 PAVIA clinical trial in NPDR in the second quarter of this year and to initiate the first pivotal Phase 3 wAMD trial, the LUGANO trial, in the second half of this year, with the second pivotal wAMD trial called the LUCIA trial to follow.

 

In January 2024, we initiated our third Phase 2 clinical trial for DURAVYU, the VERONA trial for diabetic macular edema (DME), and we look forward to reporting topline results in the first quarter of 2025.

DURAVYU brings a new mechanistic approach to the treatment of VEGF-mediated retinal diseases by combining zero order kinetic release and pan-VEGF receptor inhibition, inhibiting the effects of all VEGF isoforms, resulting in enhanced efficacy and extended durability. We remain highly encouraged by the growing body of positive clinical data for DURAVYU and its potential as a differentiated therapeutic option with sustained delivery over 6-9 months, and we are optimistic that DURAVYU has the potential to change the current treatment paradigm for VEGF-mediated retinal diseases.

Turning to our early pipeline, in 2023 we announced a new preclinical program, EYP-2301, which delivers a promising TIE-2 agonist, razuprotafib, formulated in Durasert E™. We believe that delivering EYP-2301 intravitreally has the potential to offer new sight-saving treatment for patients with severe retinal disease, either alone or in combination with anti-VEGFs. We continue to evaluate additional molecules for sustained delivery in Durasert E™ including complement inhibition and rare diseases and hope to update you on those programs later this year.

In addition, we significantly strengthened our balance sheet with the May 2023 out-license of YUTIQ® for $82.5 million plus future royalties and the December 2023 completion of a successful $230 million follow-on equity financing. We ended the year well-capitalized with cash and investments of $331 million with no debt.

 

 

 

 

 


 

 

When it comes to matters of sight, innovation is our vision.

 

 

 

 

 

To support our pipeline progress and meet the long-term needs of our patients, employees and shareholders, we completed a number of significant milestones in 2023 and in recent months. This includes the completion of the transition of Jay S. Duker, M.D. to President and CEO from his previous role as Chief Operating Officer and the transition of Nancy S. Lurker from CEO to Executive Vice Chair of the Board of Directors. We also appointed Stuart Duty, a seasoned veteran in biotech finance and investment banking, to EyePoint’s Board of Directors and Ramiro Ribeiro, M.D., Ph.D. as Chief Medical Officer. Dr. Ribeiro joins EyePoint from Apellis Pharmaceuticals, where he served as Vice President, Head of Clinical Development. Additionally, we promoted our Chief Financial Officer George Elston to Executive Vice President, underscoring his invaluable contributions to EyePoint’s organizational growth, financial success and strategic long-term vision. We would also like to thank Victor Liu for his years of service to EyePoint’s Board of Directors and important support of our Company during his tenure.

We are grateful for the dedicated and talented team at EyePoint who continue to drive our progress and are responsible for our company’s clinical, operational, and financial success to date. In addition, we’d like to thank the patients and clinical investigators for their participation in our ongoing trials; without whom, our progress advancing DURAVYU would not be possible. With our compelling clinical pipeline representing potential multi-billion-dollar product opportunities, our best-in-class sustained ocular delivery Durasert E™ technology, along with a strong balance sheet, we're well-positioned to grow as a leader in ocular drug delivery with the potential to benefit the millions of patients at risk of serious vision loss.

 

 

On behalf of the entire EyePoint team and Board of Directors, we thank you, our committed stockholders, for your continued support as we work towards providing better solutions for patients with serious retinal diseases – because when it comes to matters of sight, innovation is our vision.

Sincerely,

 

 

https://cdn.kscope.io/bfecb590142cdff561e6cf23de2272da-img83600834_1.jpg 

 

Jay S. Duker, M.D.

President & Chief Executive Officer

 


https://cdn.kscope.io/bfecb590142cdff561e6cf23de2272da-img83600834_2.jpg 

Goran Ando, M.D.

Chairman of the Board

 

 

DURAVYU™ has been conditionally accepted by the FDA as the proprietary name for EYP-1901. DURAVYU is an investigational product; it has not been approved by the FDA. FDA approval and the timeline for potential approval is uncertain.

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 


 

 

 

 

SAFE HARBOR STATEMENTS UNDER THE PRIVATE SECURITIES LITIGATION ACT OF 1995: To the extent any statements made in this proxy deal with information that is not historical, these are forward-looking statements under the Private Securities Litigation Reform Act of 1995. Such statements include, but are not limited to, statements identified by words such as “will,” “potential,” “could,” “can,” “believe,” “intends,” “continue,” “plans,” “expects,” “anticipates,” “estimates,” “may,” other words of similar meaning or the use of future dates. Forward-looking statements by their nature address matters that are, to different degrees, uncertain. Uncertainties and risks may cause EyePoint’s actual results to be materially different than those expressed in or implied by EyePoint’s forward-looking statements. For EyePoint, this includes uncertainties regarding the timing and clinical development of our product candidates, including EYP-1901 and EYP-2301; the potential for EYP-1901 as a novel sustained delivery treatment for serious eye diseases, including wet age-related macular degeneration and non-proliferative diabetic retinopathy and diabetic macular edema ; the effectiveness and timeliness of clinical trials, and the usefulness of the data; the timeliness of regulatory approvals including potential U.S. Food and Drug Administration (FDA) regulatory approval of EYP-1901 and EYP-2301; the success of current and future license agreements; our dependence on contract research organizations, and other outside vendors and service providers; the success of Durasert E™ as a drug delivery platform in FDA approved products; product liability; industry consolidation; compliance with environmental laws; volatility of stock price; possible dilution; absence of dividends; the impact of general business and economic conditions; instability in macroeconomic factors including changes in inflation, interest rates and the labor market; protection of our intellectual property and avoiding intellectual property infringement; retention of key personnel; manufacturing risks; and other factors described in our filings with the Securities and Exchange Commission. We cannot guarantee that the results and other expectations expressed, anticipated or implied in any forward-looking statement will be realized. A variety of factors, including these risks, could cause our actual results and other expectations to differ materially from the anticipated results or other expectations expressed, anticipated or implied in our forward-looking statements. Should known or unknown risks materialize, or should underlying assumptions prove inaccurate, actual results could differ materially from past results and those anticipated, estimated or projected in the forward-looking statements. You should bear this in mind as you consider any forward-looking statements. Our forward-looking statements speak only as of the dates on which they are made. EyePoint undertakes no obligation to update or revise any forward-looking statement, whether as a result of new information, future events, or otherwise.

 


 

https://cdn.kscope.io/bfecb590142cdff561e6cf23de2272da-img83600834_3.jpg 

 

 

NOTICE OF 2024 ANNUAL MEETING OF STOCKHOLDERS

TO BE HELD JUNE 20, 2024

 

Dear Stockholders:

NOTICE IS HEREBY GIVEN that the 2024 Annual Meeting of Stockholders (Annual Meeting) of EyePoint Pharmaceuticals, Inc. (the Company) will be held on June 20, 2024 at 9:00 a.m., Eastern Time. This year’s Annual Meeting will be a virtual meeting via live webcast on the Internet. You will not be able to attend the Annual Meeting in person. Instead, you will be able to attend the Annual Meeting by visiting www.meetnow.global/MWRWKS9, for the following purposes:

1.
To elect nine directors to the Company’s Board of Directors, each to serve until the Company’s 2025 Annual Meeting of Stockholders or until such person’s successor is duly elected and qualified.
2.
To approve an amendment to the EyePoint Pharmaceuticals, Inc. 2023 Long-Term Incentive Plan to (i) increase the number of shares of common stock authorized for issuance thereunder by 4,000,000 shares and (ii) increase the individual non-employee director compensation limit contained therein to $850,000 for ongoing directors in any calendar year and $1,100,000 for new directors in any calendar year.
3.
To approve an amendment to the EyePoint Pharmaceuticals, Inc. 2019 Employee Stock Purchase Plan to increase the number of shares of common stock authorized for issuance thereunder by 250,000 shares.
4.
To approve, on an advisory basis, the compensation paid to the Company’s named executive officers as disclosed in the accompanying proxy statement.
5.
To ratify the appointment of Deloitte & Touche LLP as the Company’s independent registered public accounting firm for the fiscal year ending December 31, 2024.
6.
To transact such other business as may properly come before the meeting or any adjournment or postponement of the Annual Meeting.

The Company’s Board of Directors recommends that stockholders vote FOR ALL on Proposal No. 1 and FOR Proposal Nos. 2, 3, 4 & 5. During the ten days before the Annual Meeting, you may inspect a list of stockholders eligible to vote. If you would like to inspect the list, please call Jason D. Herpel, Vice President and Associate General Counsel, at (215) 817-4705 to arrange the inspection.

Stockholders of record at the close of business on April 23, 2024, the record date of the Annual Meeting, are entitled to notice of, and to vote at, the Annual Meeting and any adjournment or postponement of the meeting.

Important notice regarding the availability of proxy materials for the Annual Meeting to be held on June 20, 2024. Our 2024 Proxy Statement and Annual Report on Form 10-K for the year ended December 31, 2023 are available at www.edocumentview.com/EYPT for street holders and www.envisionreports.com/EYPT for registered holders.

The accompanying proxy statement includes further details with respect to the proposals to be considered at the Annual Meeting. This notice of Annual Meeting and the accompanying proxy statement contain important information and should be read in their entirety. If you are in doubt as to how you should vote at the Annual Meeting, you should seek advice from your legal counsel, accountant, or other professional adviser prior to voting.

 

 

By Order of the Board of Directors

 

 

https://cdn.kscope.io/bfecb590142cdff561e6cf23de2272da-img83600834_4.jpg 

 

 

Ron Honig

 

Chief Legal Officer and Company Secretary

April 26, 2024

 


 

Watertown, Massachusetts

 


 

Table of Contents

QUESTIONS AND ANSWERS ABOUT THE PROXY MATERIALS AND VOTING

 

1

 

 

 

DIRECTORS AND EXECUTIVE OFFICERS

 

8

 

 

 

CORPORATE GOVERNANCE AND BOARD MATTERS

 

13

 

 

 

STOCK OWNERSHIP

 

22

 

 

 

EXECUTIVE OFFICER AND DIRECTOR COMPENSATION

 

24

 

 

 

PAY VERSUS PERFORMANCE DISCLOSURE

 

35

 

 

 

PROPOSAL 1: ELECTION OF NINE DIRECTORS

 

39

 

 

 

PROPOSAL 2: APPROVAL OF AMENDMENT TO 2023 LONG-TERM INCENTIVE PLAN

 

40

 

 

 

PROPOSAL 3: APPROVAL OF AMENDMENT TO 2019 EMPLOYEE STOCK PURCHASE PLAN

 

46

 

 

 

PROPOSAL 4: ADVISORY VOTE ON EXECUTIVE COMPENSATION

 

49

 

 

 

PROPOSAL 5: RATIFICATION OF APPOINTMENT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM

 

50

 

 

 

INFORMATION ABOUT STOCKHOLDER PROPOSALS AND DIRECTOR NOMINATIONS

 

52

 

 

 

DELIVERY OF DOCUMENTS TO STOCKHOLDERS SHARING AN ADDRESS

 

52

 

 

 

AVAILABILITY OF ANNUAL REPORT ON FORM 10-K

 

52

 

 

 

OTHER BUSINESS

 

53

 

 

 

ANNEX A: AMENDMENT TO 2023 LONG TERM INCENTIVE PLAN AND THE 2023 LONG TERM INCENTIVE PLAN

 

A-1

 

 

 

ANNEX B: AMENDMENT TO 2019 EMPLOYEE STOCK PURCHASE PLAN AND THE 2019 EMPLOYEE STOCK PURCHASE PLAN

 

A-12

 

 

 

In this proxy statement, the words “EyePoint,” “the Company,” “we,” “our,” “ours,” “us”, and similar terms refer to EyePoint Pharmaceuticals, Inc. and its consolidated subsidiaries, unless the context indicates otherwise.

The Notice of 2024 Annual Meeting of Stockholders and Proxy Statement and our accompanying Annual Report on Form 10-K are being distributed and made available on or about May 6, 2024.

 


 

https://cdn.kscope.io/bfecb590142cdff561e6cf23de2272da-img83600834_5.jpg 

 

QUESTIONS AND ANSWERS

ABOUT

THE PROXY MATERIALS AND VOTING

Proxy Materials

 

Why am I receiving these proxy materials?

Our Board of Directors (Board) has made these proxy materials available to you on the Internet, or, upon your request, has delivered a printed or email copy of these proxy materials to you, in connection with its solicitation of proxies for use at our 2024 Annual Meeting of Stockholders (Annual Meeting), which will take place on Thursday, June 20, 2024 at 9:00 a.m., Eastern Time, via live webcast on the Internet by visiting www.meetnow.global/MWRWKS9. We began sending the Notice of Internet Availability of Proxy Materials (Notice) on or about May 6, 2024. You received proxy materials because you owned shares of EyePoint common stock at the close of business on April 23, 2024 (Record Date), and that entitles you to vote at the Annual Meeting. These proxy materials describe the matters on which our Board would like you to vote and contain information that we are required to provide to you under the rules of the U.S. Securities and Exchange Commission (SEC) when we solicit your proxy.

IMPORTANT NOTICE REGARDING THE AVAILABILITY OF PROXY MATERIALS FOR THE ANNUAL MEETING TO BE HELD ON JUNE 20, 2024. Our 2024 Proxy Statement and Annual Report on Form 10-K for the year ended December 31, 2023 are available at www.edocumentview.com/EYPT for street holders and www.envisionreports.com/EYPT for registered holders.

What is included in the proxy materials?

The proxy materials include:

the Notice of 2024 Annual Meeting of Stockholders and Proxy Statement (Proxy Statement);
our Annual Report on Form 10-K for the year ended December 31, 2023 (Annual Report); and
if you requested a printed or email copy of these proxy materials, the proxy or voting instruction card that accompanied these materials.

What information is contained in this Proxy Statement and our Annual Report on Form 10-K?

The information in this Proxy Statement relates to the proposals to be voted on at the Annual Meeting, the voting process, the compensation of our directors and certain of our executive officers, corporate governance matters, and certain other required information. Our Annual Report contains information about our business, our audited financial statements and other important information that we are required to disclose under the rules of the SEC.

Why did I receive a notice in the mail regarding the Internet availability of proxy materials instead of a full set of proxy materials?

In accordance with SEC rules, we may furnish proxy materials, including this Proxy Statement and our Annual Report, to our stockholders by providing access to such documents on the Internet instead of mailing printed copies. Most stockholders will not receive printed copies of the proxy materials unless they request them. Instead, the Notice will instruct you as to how you may access and review all of the proxy materials on the Internet. The Notice also instructs you as to how you may submit your proxy or voting instructions on the Internet. If you would like to receive a paper or email copy of the proxy materials, you should follow the instructions in the Notice for requesting such materials.

1


 

How can I access the proxy materials over the Internet?

The Notice and, if you requested to receive a printed or email copy of these proxy materials, the proxy or voting instruction card that accompanied these materials, contains instructions on how to:

view the proxy materials for the Annual Meeting on the Internet and vote your shares; and
instruct us to send our future proxy materials to you electronically by email.

Our proxy materials are also available at www.edocumentview.com/EYPT for street holders and www.envisionreports.com/EYPT for registered holders.

Choosing to receive your future proxy materials by email will save us the cost of printing and mailing documents to you. If you choose to receive future proxy materials by email, you will receive an email next year with instructions containing a link to those materials and a link to the proxy voting site. Your election to receive proxy materials by email will remain in effect until you revoke it.

Voting Information

 

What items of business will be voted on at the Annual Meeting?

The items of business scheduled to be voted on at the Annual Meeting are:

 

Proposal No. 1:

To elect nine members of our Board of Directors, each to serve until our 2025 Annual Meeting of Stockholders or until such person’s successor is duly elected and qualified.

 

 

Proposal No. 2:

To approve an amendment to the EyePoint Pharmaceuticals, Inc. 2023 Long-Term Incentive Plan to (i) increase the number of shares of common stock authorized for issuance thereunder by 4,000,000 shares and (ii) increase the individual non-employee director compensation limit contained therein to $850,000 for ongoing directors in any calendar year and $1,100,000 for new directors in any calendar year.

 

 

Proposal No. 3:

To approve an amendment to the EyePoint Pharmaceuticals, Inc. 2019 Employee Stock Purchase Plan to increase the number of shares of common stock authorized for issuance thereunder by 250,000 shares.

 

 

Proposal No. 4:

To approve, on an advisory basis, the compensation paid to our named executive officers, as described in this proxy statement.

 

 

Proposal No. 5

To ratify the appointment of Deloitte & Touche LLP as our independent registered public accounting firm for the fiscal year ending December 31, 2024

 

See the “Proposals” section of this Proxy Statement for information on these proposals. We will also consider any other business that is properly brought before the Annual Meeting or any adjournments or postponements thereof. See “What happens if additional matters are presented at the Annual Meeting?” below.

How does the Board of Directors recommend that I vote?

Our Board recommends that you vote your shares as follows:

 

Board
Recommendation

 

 

 

Proposal No. 1:

The election of nine members of our Board of Directors, each to serve until our 2025 Annual Meeting of Stockholders or until such person’s successor is duly elected and qualified.

FOR ALL

 

 

 

Proposal No. 2:

To approve an amendment to the EyePoint Pharmaceuticals, Inc. 2023 Long-Term Incentive Plan to (i) increase the number of shares of common stock authorized for issuance thereunder by 4,000,000 shares and (ii) increase the individual non-employee director compensation limit contained therein to $850,000 for ongoing directors in any calendar year and $1,100,000 for new directors in any calendar year.

FOR

2


 

 

 

 

 

 

 

Proposal No. 3:

To approve an amendment to the EyePoint Pharmaceuticals, Inc. 2019 Employee Stock Purchase Plan to increase the number of shares of common stock authorized for issuance thereunder by 250,000 shares.

FOR

 

 

 

Proposal No. 4:

To approve, on an advisory basis, the compensation paid to our named executive officers, as described in this proxy statement.

FOR

 

 

 

Proposal No. 5

To ratify the appointment of Deloitte & Touche LLP as our independent registered public accounting firm for the fiscal year ending December 31, 2024

FOR

 

See the “Proposals” section of this Proxy Statement for information on these proposals and our Board’s recommendations.

What happens if additional matters are presented at the Annual Meeting?

Other than the five items of business described in this Proxy Statement, we are not aware of any other business to be acted upon at the Annual Meeting. If you grant a proxy, the persons named as proxy holders, Jay S. Duker, Chief Executive Officer and Ron I. Honig, Chief Legal Officer and Company Secretary, or either of them, will have the discretion to vote your shares on any additional matters properly presented for a vote at the Annual Meeting or any adjournments or postponements thereof. If, for any reason, any of the director nominees is not available as a candidate for director, the persons named as proxy holders will vote your proxy for such other candidate or candidates as may be nominated by our Board of Directors.

How many votes do I have?

There were 52,084,148 shares of common stock issued and outstanding as of the close of business on the Record Date. Each share of our common stock that you owned as of the Record Date entitles you to one vote on each matter presented at the Annual Meeting. Cumulative voting for directors is not permitted.

What is the difference between holding shares as a “stockholder of record” as compared to as a “beneficial owner”?

Most of our stockholders hold their shares as a beneficial owner through a broker, bank, trust or other nominee rather than directly in their own name. As summarized below, there are some distinctions between shares held of record and those owned beneficially.

Stockholder of Record: If your shares are registered directly in your name with our transfer agent, Computershare Trust Company N.A. (Computershare), you are considered, with respect to those shares, the stockholder of record. As the stockholder of record, you have the right to grant your voting proxy directly to us or to vote personally at the Annual Meeting. You will need the control or account number included in the e-mailed Notice, or your proxy card, if you received a paper notice, in order to be able to vote your shares or submit questions during the Annual Meeting. If you do not wish to vote personally or you will not be attending the Annual Meeting, you may vote by proxy over the Internet by following the instructions provided in the Notice, or, if you requested a printed or email copy of these proxy materials, you can also vote by telephone or mail by following the instructions contained in the proxy card that accompanied these materials. See “How can I vote my shares without attending the Annual Meeting?” below.
Beneficial Owner: If your shares are held through a broker, bank, trust or other nominee, like the majority of our stockholders, you are considered the beneficial owner of shares held in street name, and the Notice was forwarded to you by that organization. The organization holding your account is considered to be the stockholder of record for purposes of voting at the Annual Meeting. As the beneficial owner, you have the right to direct your broker, bank, trustee, or other nominee how to vote the shares in your account. Since a beneficial owner is not the stockholder of record, you may not vote your shares personally at the Annual Meeting unless you obtain a “legal proxy” from the broker, bank, trustee, or other nominee that holds your shares giving you the right to vote the shares at the Annual Meeting. If you do not wish to vote personally or you will not be attending the Annual Meeting, you may vote by proxy over the Internet by following the instructions provided in the Notice, or, if you requested a printed or email copy of these proxy materials, you can also vote by telephone or by mail by following the instructions on the voting instruction card provided to you by your broker, bank, trustee, or other nominee. See “How can I vote my shares without attending the Annual Meeting?” below.

3


 

How can I vote my shares personally at the Annual Meeting?

You may vote your shares held in your name as the stockholder of record personally while participating in the Annual Meeting live via the Internet at www.meetnow.global/MWRWKS9 using your unique control number that was included in the Notice that you received in the mail, or, if you requested to receive a printed or email copy of these proxy materials, the proxy card that accompanied these materials.

If your shares are held beneficially in street name, you may still vote them at the Annual Meeting live via the Internet at www.meetnow.global/MWRWKS9 only if you obtain a legal proxy from the broker, bank, trustee, or other nominee that holds your shares giving you the right to vote the shares. Even if you plan to attend the Annual Meeting live via the Internet, we recommend that you also submit your proxy or voting instructions as described below so that your vote will be counted if you later decide not to attend the Annual Meeting personally.

How can I vote my shares without attending the Annual Meeting?

Whether you hold shares directly as the stockholder of record or beneficially in street name, you may direct how your shares are voted without attending the Annual Meeting.

Stockholder of Record: If you are a stockholder of record, you may vote by proxy. You can vote by proxy over the Internet by following the instructions provided in the Notice, or, if you requested a printed or email copy of these proxy materials, you can also vote by telephone or mail by following the instructions on the proxy card that accompanied these materials.
Beneficial Owner: If you hold shares beneficially in street name, you may also vote by proxy over the Internet by following the instructions provided in the voting instructions provided to you by your broker, bank, trustee or other nominee, or, if you requested to receive a printed or email copy of these proxy materials, you can also vote by telephone or mail by following the instructions on the voting instruction card provided to you by your broker, bank, trustee, or other nominee.

Can I change my vote or revoke my proxy?

If you are the stockholder of record, you may change your vote at any time prior to the taking of the vote at the Annual Meeting by:

granting a new proxy bearing a later date by following the instructions provided in the Notice or, if you requested to receive a printed or email copy of these proxy materials, the proxy card that accompanied these materials;
providing a written notice of revocation to our Company Secretary at 480 Pleasant Street, Suite C400, Watertown, MA 02472, which notice must be received by our Company Secretary before the Annual Meeting; or
attending the Annual Meeting live via the Internet and voting personally.

If you hold shares beneficially in street name, you may change your vote by:

submitting new voting instructions to your broker, bank, trustee, or other nominee by following the instructions provided in the voting instructions sent to you by your broker, bank, trustee or other nominee; or,
if you have obtained a valid legal proxy and control number from your broker, bank, trustee, or other nominee giving you the right to vote your shares, by attending the Annual Meeting via the Internet and voting personally using the valid legal proxy.

 

Note that for both stockholders of record and beneficial owners, attendance at the Annual Meeting will not cause your previously granted proxy or voting instructions to be revoked unless you specifically so request or vote via the Internet personally at the Annual Meeting.

Is my vote confidential?

Proxy instructions, ballots, and voting tabulations that identify individual stockholders are handled in a manner that protects your voting privacy. Your vote will not be disclosed either within our Company or to third parties, except: (1) as necessary to meet applicable legal requirements, (2) to allow for the tabulation of votes and certification of the vote, and (3) to facilitate a successful proxy solicitation.

4


 

What is a “broker non-vote”?

If you are a beneficial owner of shares held by a broker, bank, trust or other nominee and you do not provide your broker, bank, trustee or other nominee with voting instructions, your shares may constitute “broker non-votes.” Broker non-votes occur on a matter when the broker, bank, trustee or other nominee is not permitted under applicable stock exchange rules to vote on that matter without instructions from the beneficial owner and instructions are not given. These matters are referred to as “non-routine” matters.

Proposal Nos. 1, 2, 3 and 4 are considered “non-routine” matters, while Proposal No. 5 is considered a “routine” matter. Therefore, if you are a beneficial owner of shares held in street name and do not provide voting instructions, your shares will not be voted on Proposal Nos. 1, 2, 3 and 4 and a broker non-vote will occur on these matters. In tabulating the voting result for any particular proposal, shares that constitute broker non-votes are not considered votes cast with respect to that proposal. Thus, broker non-votes will not affect the outcome of any matter being voted on at the Annual Meeting, assuming that a quorum is obtained. Because Proposal No. 5 is a “routine” matter, a broker, bank, trustee, or other nominee will be permitted to exercise its discretion on this proposal, which means there will be no broker non-votes on this matter.

How many shares must be present or represented to conduct business at the Annual Meeting?

A “quorum” is necessary to conduct business at the Annual Meeting. A quorum is established if the holders of one-third of all shares issued and outstanding and entitled to vote at the Annual Meeting are present at the Annual Meeting, either in person via virtual communication or represented by proxy. Abstentions and broker non-votes will be counted as present for purposes of determining a quorum at the Annual Meeting. If a quorum is not present, the Annual Meeting will be adjourned until a quorum is obtained.

What are the voting requirements to approve the proposals discussed in this Proxy Statement?

Proposal No. 1: Election of nine directors to the Board. Votes may be cast: FOR ALL nominees, WITHHOLD ALL nominees or FOR ALL EXCEPT those nominees noted by you on the appropriate portion of your proxy or voting instructions. A plurality of the votes of the shares present personally or represented by proxy at the Annual Meeting is required to elect director nominees, and as such, the nine nominees who receive the greatest number of votes cast by stockholders entitled to vote on the matter will be elected. Broker non-votes and abstentions will have no effect on the outcome of this proposal.
Proposal No. 2: Approve an amendment to the EyePoint Pharmaceuticals, Inc. 2023 Long-Term Incentive Plan to (i) increase the number of shares of common stock authorized for issuance thereunder by 4,000,000 shares and (ii) increase the individual non-employee director compensation limit contained therein to $850,000 for ongoing directors in any calendar year and $1,100,000 for new directors in any calendar year. Votes may be cast: FOR, AGAINST or ABSTAIN. The approval of this Proposal No. 2 requires the affirmative vote of a majority of the votes properly cast on the matter. Broker non-votes and abstentions will have no effect on the outcome of this proposal.
Proposal No. 3: Approve an amendment to the EyePoint Pharmaceuticals, Inc. 2019 Employee Stock Purchase Plan to increase the number of shares of common stock authorized for issuance thereunder by 250,000 shares. Votes may be cast: FOR, AGAINST or ABSTAIN. The approval of this Proposal No. 3 requires the affirmative vote of a majority of the votes properly cast on the matter. Broker non-votes and abstentions will have no effect on the outcome of this proposal.
Proposal No. 4: Approve, on an advisory basis, the compensation paid to our named executive officers as disclosed in this proxy statement. Votes may be cast: FOR, AGAINST or ABSTAIN. The approval of this Proposal No. 4 requires the affirmative vote of a majority of the votes properly cast on the matter. Broker non-votes and abstentions will have no effect on the outcome of this proposal.
Proposal No. 5: Ratification of the appointment of Deloitte & Touche LLP as our independent registered public accounting firm for the fiscal year ending December 31, 2024. Votes may be cast: FOR, AGAINST or ABSTAIN. The approval of this Proposal No. 5 requires the affirmative vote of a majority of the votes properly cast on the matter. Broker non-votes will not occur in connection with this proposal because brokers, banks, trustees, and other nominees have discretionary voting authority to vote shares on this proposal under stock exchange rules without specific instructions from the beneficial owner of such shares. Abstentions will have no effect on the outcome of this proposal.

5


 

Who will bear the cost of soliciting votes for the Annual Meeting?

We will pay the entire cost of preparing, assembling, printing, mailing and distributing these proxy materials, and soliciting votes. Our directors, officers, and employees may solicit proxies or votes in person, by telephone or by electronic communication. We will not pay our directors, officers, or employees any additional compensation for these services. We will ask brokers, banks, trustees, and other nominees to forward the proxy materials to their principals and to obtain authority to execute proxies and will reimburse them for certain costs in connection therewith.

Who will count the votes?

Votes will be counted by the inspector of election appointed for the Annual Meeting.

Where can I find the voting results of the Annual Meeting?

We will announce preliminary voting results at the Annual Meeting and disclose the final voting results in a Current Report on Form 8-K that we will file with the SEC within four business days of the Annual Meeting.

Attending the Annual Meeting

 

Why is the Annual Meeting being held virtually?

By hosting the Annual Meeting online, we are able to communicate more effectively with our stockholders, enable increased attendance and participation from locations around the world, and reduce costs for both EyePoint and its stockholders. The virtual meeting has been designed to provide the same rights to participate as you would have at an in-person meeting. You will be able to vote online during the Annual Meeting, change a vote you may have submitted previously, or ask questions online that will be reviewed and answered by the speakers. You will only be able to participate in this manner if you log in with your holder control number.

Can I submit a question for the Meeting?

Stockholders who attend the Annual Meeting by webcast by visiting www.meetnow.global/MWRWKS9 will have an opportunity to submit questions in writing during a portion of the Annual Meeting. Instructions for submitting a question during the Annual Meeting will be provided on the Annual Meeting website. We will endeavor to answer as many submitted questions as time permits; however, we reserve the right to exclude questions regarding topics that are not pertinent to Annual Meeting matters or company business or are inappropriate. If we receive substantially similar questions, we will group such questions together and provide a single response to avoid repetition. Any questions that are appropriate and pertinent to the Annual Meeting but cannot be answered during the Annual Meeting due to time constraints will be answered and posted on the “Investors – Governance Documents” page of our Company’s website at www.eyepointpharma.com, as soon as practicable after the Annual Meeting.

What should I do if I need technical support during the Annual Meeting?

The Annual Meeting platform is fully supported across browsers and devices running the most updated version of applicable software and plugins. Attendees should ensure they have a strong internet connection, allow plenty of time to log in, and confirm they can hear streaming audio prior to the start of the Annual Meeting.

If you experience any technical difficulties accessing the Annual Meeting or during the Annual Meeting, please call the toll-free number that will be available on our virtual stockholder login site at www.meetnow.global/MWRWKS9 for assistance. We will have technicians ready to assist you with any technical difficulties you may have beginning 15 minutes prior to the start of the Annual Meeting, and the technicians will be available through the conclusion of the Annual Meeting. Additional information regarding matters addressing technical and logistical issues, including technical support during the Annual Meeting, will be available on the Annual Meeting website.

6


 

How can I attend the Annual Meeting?

The Annual Meeting will be a completely virtual meeting of stockholders, which will be conducted exclusively by webcast. You are entitled to participate in the Annual Meeting only if you were a stockholder of the Company as of the close of business on the Record Date, or if you hold a valid proxy for the Annual Meeting. No physical meeting will be held.

You will be able to attend the Annual Meeting online and submit your questions during the meeting by visiting www.meetnow.global/MWRWKS9. You also will be able to vote your shares online by attending the Annual Meeting by webcast. To participate in the Annual Meeting, you will need to review the information included on your Notice, on your proxy card or on the instructions that accompanied your proxy materials.

If you hold your shares through an intermediary, such as a bank or broker, you must register in advance using the instructions below.

The online meeting will begin promptly at 9:00 a.m., Eastern Time. We encourage you to access the meeting at least 15 minutes prior to the start time and to leave ample time for the check in. Please follow the registration instructions as outlined in this proxy statement.

How do I register to attend the Annual Meeting virtually on the Internet?

Stockholder of Record: If you are a stockholder of record (i.e., you hold your shares through our transfer agent, Computershare), you do not need to register to attend the Annual Meeting virtually on the Internet. Please follow the instructions on the notice or proxy card that you received.
Beneficial Owner: If you hold your shares through a broker, bank, trustee or other nominee, you must register in advance to attend the Annual Meeting virtually on the Internet. To register to attend the Annual Meeting online by webcast you must submit proof of your proxy power (i.e. the legal proxy you obtained from the broker, bank, trustee or other nominee) reflecting your Company holdings along with your name and email address to Computershare. Requests for registration must be labeled as “Legal Proxy” and be received no later than 5:00 p.m., Eastern Time, on June 17, 2024.

You will receive a confirmation of your registration by email after we receive your registration materials.

Requests for registration should be directed to us at the following:

By email:

Forward the email from your broker, or attach an image of your legal proxy, to legalproxy@computershare.com.

By mail:

Computershare

EyePoint Pharmaceuticals, Inc. Legal Proxy

P.O. Box 43001

Providence, RI 02940-3001

7


 

DIRECTORS AND EXECUTIVE OFFICERS

Directors and Director Nominees

Our Board consists of ten (10) directors. The term of each director expires each year at our Annual Meeting of Stockholders. Each director also continues to serve as a director until his or her successor is duly elected and qualified, or until he or she sooner dies, resigns, or is removed. Ye Liu will not stand for re-election at our annual Meeting but will continue to serve as a director until the expiration of his term at the Annual Meeting. The size of the Board will be reduced to nine (9) members as of the Annual Meeting.

The following table sets forth the name, age, director service period and position of each of our current directors and director nominees as of April xx, 2024, other than Mr. Liu who will not stand for re-election at our Annual Meeting:

 

Name

 

Age

 

Position

 

Director Since

Göran Ando, M.D.

 

75

 

Chair of the Board of Directors

 

2018

Jay S. Duker, M.D.

 

65

 

President, Chief Executive Officer and Director

 

2016-2020,

2023

Nancy Lurker

 

66

 

Executive Vice Chair of the Board of Directors

 

2016

John B. Landis, Ph.D.

 

71

 

Director

 

2018

David Guyer, M.D.

 

64

 

Director

 

2019

Wendy DiCicco

 

56

 

Director

 

2019

Anthony P. Adamis, M.D.

 

65

 

Director

 

2022

Karen Zaderej

 

62

 

Director

 

2022

Stuart Duty

 

59

 

Director

 

2023

 

 

 

 

 

 

 

 

Board Diversity Matrix

The following Board Diversity Matrix presents our Board diversity statistics in accordance with Nasdaq Rule 5606, as self-disclosed by our directors and director nominee:

 

Board Diversity Matrix (As of April 26, 2024)

Total Number of Directors

10

 

Female

Male

Non-Binary

Did Not Disclose Gender

Part I: Gender Identity

 

Directors

3

7

0

0

Part II: Demographic Background

African American or Black

0

0

0

0

Alaskan Native or Native American

0

0

0

0

Asian

0

1

0

0

Hispanic or Latinx

0

0

0

0

Native Hawaiian or Pacific Islander

0

0

0

0

White

3

6

0

0

Two or More Races or Ethnicities

0

0

0

0

LGBTQ+

0

Did Not Disclose Demographic Background

0

 

The diversity matrix of our Board of Directors for the year ended December 31, 2022 is available in our proxy statement for the 2023 annual meeting of our stockholders, filed with the SEC on April 14, 2023.

 

Set forth below for each director standing for election at the Annual Meeting is a list of Board Committee memberships and a description of his or her business experience, qualifications, education and skills that led our Board to conclude that such individual should serve as a member of our Board:

Göran Ando, M.D.

Chair of the Board and the Governance and Nominating Committee, member of the Compensation Committee and the Science Committee

8


 

Dr. Ando has had a distinguished career in the global pharmaceutical industry that has spanned nearly four decades. He began his career at Pfizer, Inc., where he held several senior clinical positions both in the U.S. and in Europe. Dr. Ando also served as President of the Astra Research Centre. He held various senior appointments at GlaxoSmithKline plc, including Research and Development Director for Glaxo Group Research. Dr. Ando then joined Pharmacia AB in 1995 as Executive Vice President and Deputy Chief Executive Officer to lead Research and Development with additional responsibilities for manufacturing, information technology, business development, and M&A. During his nine-year tenure as Head of Research and Development at Pharmacia/Pharmacia & Upjohn, 17 new drugs were approved by the FDA prior to Pharmacia’s acquisition by Pfizer for $60 billion. Dr. Ando retired in 2018 as Chairman of Novo Nordisk A/S and previously served as the Chief Executive Officer of Cell Tech Group PLC from 2003 to 2005. He currently serves as Chairman of the Board for Nouscom A/G (a private company in Switzerland) and Nanexa AB (Sweden). Previously, he has served as Chairman of the Board for several European-based biopharmaceutical companies, and, until April 2020, he served as a board member of Molecular Partners (a public company listed on the Swiss exchange). He served as a Senior Advisor at EW Healthcare Partners from 2007 to July 2021. From December 2020 to December 2022, Dr. Ando served as a Director of the Board for Selecta Bio (NASDAQ: SELB). Dr. Ando received his Bachelor of Arts degree from Uppsala University in Sweden and Doctor of Medicine degree from Linköping University in Sweden.

We believe Dr. Ando is qualified to serve as Chair of our Board because his strong record of leadership as an executive officer and director in the life sciences industry affords him a deep understanding of the industry and corporate setting in which we operate and allows him to impart his substantial expertise in the fields of manufacturing, information technology, business development and commercialization to the Board and the Company.

Jay S. Duker, M.D

 

President, Chief Executive Officer and Director



Dr. Duker has been EyePoint’s President, Chief Executive Officer and a Director since July 2023. Prior to these roles, Dr. Duker served EyePoint as President and Chief Operating Officer and as Chief Strategic Scientific Officer. He was an independent Director on EyePoint’s Board of Directors from 2016-2020 before his re-appointment to the Board of Directors in July 2023.

Between 2001 and 2021, Dr. Duker was the Director of the New England Eye Center (NEEC) and Professor and Chair of the Department of Ophthalmology at Tufts Medical Center and the Tufts University School of Medicine in Boston, Massachusetts. He has published over 345 journal articles, concentrating on retinal imaging, retinal vascular diseases, and drug delivery to the posterior segment. Dr. Duker remains in clinical practice, seeing patients with medical retinal disorders and intraocular tumors. Dr. Duker is the founder of three successful start-up companies; SurgiSite Boston, the fifth busiest independent ophthalmology-only out-patient surgery center in the United States, the Boston Image Reading Center (BIRC), and Hemera Biosciences, the developer of HMR59, an AAV-based gene therapy for dry age-related macular degeneration that is currently in a phase 2 clinical trial after being acquired by Janssen in 2020. Dr. Duker was on the Board of Sesen Bio and served as its Chair until March 2023. Dr. Duker received an A.B. from Harvard University and an M.D. from the Jefferson Medical College of Thomas Jefferson University.

Dr. Duker has devoted more than 30 years to the field of ophthalmology focused on improving eyesight and preventing blindness, holding roles in clinical research, business, and academic settings. We believe Dr. Duker is qualified to serve on our Board because of his role as President and Chief Executive Officer, as well his prior service on the Board of the Company and other life science companies. Dr. Duker's extensive experience in ophthalmology, both as a renowned practitioner, scholarly leader and successful executive, provides him with valuable expertise to guide our Board.

 

Nancy Lurker

 

Executive Vice Chair of the Board of Directors

Ms. Lurker has served as Executive Vice Chair of EyePoint's Board of Directors since July 2023. Prior to this role, Ms. Lurker served as President and Chief Executive Officer of EyePoint from 2016 to July 2023. Prior to EyePoint, Ms. Lurker served as President and Chief Executive Officer and a director of PDI, Inc. (now Interpace Diagnostics Group, Inc.) (OTC: IDXG), a publicly-traded healthcare commercialization company, and as Senior Vice President and Chief Marketing Officer of Novartis Pharmaceuticals Corporation, the U.S. subsidiary of Novartis AG. Prior to that, Ms. Lurker held various senior positions at other leading pharmaceutical companies including Pharmacia Corporation (now a part of Pfizer, Inc.), ImpactRx and Bristol-Myers Squibb Company.

 

Ms. Lurker currently serves on the board of directors of Alkermes plc (Nasdaq: ALKS), Altasciences, LLC, a private contract research organization and National Sanitation Foundation, a not-for-profit organization dedicated to improving human health through

9


 

quality standards. She previously served on the boards of directors of the Cancer Treatment Centers of America, and current and formerly publicly-traded companies Aquestive Therapeutics, Inc. (NASDAQ: AQST), X4 Pharmaceuticals, Inc. (NASDAQ: XFOR), Auxilium Pharmaceuticals, Inc., Mallinckrodt plc, PDI, Inc., Elan Corporation, plc, and ConjuChem Biotechnologies. Ms. Lurker holds a B.S. in Biology from Seattle Pacific University and an M.B.A. from the University of Evansville.

 

We believe Ms. Lurker is qualified to serve on our Board because of her broad ranging experience in the pharmaceutical industry and her track record of maximizing the potential of new therapies. Ms. Lurker's years of clinical drug development at BMS, Pharmacia and Novartis, in her capacity as a senior executive, and successfully implementing innovative U.S. and global drug launches, provide her with valuable expertise and perspective on our corporate strategy, management, operations, and governance.

John B. Landis, Ph.D.

Chair of the Science Committee

Dr. Landis has served as a Director since 2018, and a GMP Consultant to EyePoint, leading the EyePoint GMP process, since December 2023. Dr. Landis served as a director for Bioanalytical Systems, Inc. (NASDAQ: BASI), from 2009 to 2017, serving as the Chairman of its board of directors from 2011 until his departure in 2017. Dr. Landis previously served as Senior Vice President, Pharmaceutical Sciences of Schering-Plough Corporation, a pharmaceutical company, from September 2003 until his retirement in October 2008. In that role, Dr. Landis led the global pharmaceutical sciences function of pharmacy, analytical chemistry, process chemistry, biotechnology, quality assurance, clinical supplies, and devices. Prior to that, Dr. Landis served as Senior Vice President, Preclinical Development at Pharmacia Corporation from 1997 until 2003 and led the global preclinical functions of toxicology, drug metabolism and pharmacokinetics, pharmaceutical sciences, analytical chemistry, and laboratory animal care. Dr. Landis also served as Vice President, Central Nervous System Psychiatry, Critical Care and Inflammation Development for Pharmacia & Upjohn from 1995 through 1997. Prior to that, Dr. Landis was employed by The Upjohn Company, where he held positions of increasing responsibility in the areas of analytical research, quality assurance, and quality control. He is a current member of Purdue University’s Drug Discovery Board. Over his career, Dr. Landis served on several other boards of directors, academic advisory panels, and professional boards. Dr. Landis earned Ph.D. and M.S. degrees in Analytical Chemistry from Purdue University and a B.S. degree in Chemistry from Kent State University.

We believe Dr. Landis is qualified to serve on the Board because his substantial and varied experience working within medical communities ranging from academia to the pharmaceutical industry position him to provide a practical and balanced perspective to the Board. Dr. Landis also brings to the Board executive experience in clinical research and his service on other public company boards affords him a deep understanding of the role of the Board and its oversight of corporate governance and business strategy.

David Guyer, M.D.

Chair of the Compensation Committee and member of the Audit Committee, Governance and Nominating Committee and the Science Committee

David R. Guyer, M.D. is a Chief Executive Officer of EyeBio, a privately held ophthalmology biotechnology company and a Venture Partner at SV Health Investors. Dr. Guyer was the co-founder and served as Executive Chairman of Iveric Bio (formerly Ophthotech) (Nasdaq: ISEE) until 2021. Dr. Guyer served as a director for Applied Genetic Technologies Corporation (Nasdaq: AGTC) from June 2014 to December 2017. Dr. Guyer served as Chairman of Iveric Bio’s board of directors since its inception in January 2007 to January 2017 and as the Chief Executive Officer from April 2013 to January 2017. Under his leadership, Ophthotech entered into one of the largest ex-US partnering transactions ever in the biotechnology industry at that time with Novartis.

Dr. Guyer has significant medical, drug development, and commercial experience in ophthalmology, and in his career has served on approximately 20 boards of both public and private companies. He co-founded Eyetech Pharmaceuticals Inc. and served as its Chief Executive Officer and as a member of its board of directors from 2000 until it was acquired by OSI Pharmaceuticals, Inc. in November 2005.

Prior to co-founding Eyetech Pharmaceuticals, Dr. Guyer was a professor and served as Chairman of the Department of Ophthalmology at New York University School of Medicine. Dr. Guyer received a BS from Yale College and an MD from Johns Hopkins Medical School. Dr. Guyer completed his ophthalmology residency at Wilmer Ophthalmological Institute, Johns Hopkins Hospital and a retinal fellowship at the Massachusetts Eye and Ear Infirmary at Harvard Medical School.

We believe Dr. Guyer is qualified to serve on the Board because of his extensive executive leadership experience, his extensive experience in ophthalmology, his extensive experience in the life sciences industry as an entrepreneur and venture capital investor, and his service on the board of directors of other life sciences companies.

10


 

Wendy DiCicco

Chair of the Audit Committee and member of the Compensation Committee and the Governance and Nominating Committee

Ms. DiCicco serves as an independent financial and board advisor to companies in the life sciences industry, often serving in the role of interim Chief Financial Officer. Since July 2023 she has served as the interim Chief Financial Officer for Akari Therapeutics (NASDAQ: AKTX). From 2019 to March 2022, she served as interim Chief Financial Officer for Renovacor, a preclinical stage biopharmaceutical company (NYSE: RCOR). Previously, she was Chief Operating and Financial Officer of Centinel Spine from 2017 to 2018, a privately-held company. Ms. DiCicco currently serves on the board of directors of Imvax, Inc a privately-held biotechnology company, and previously served on the boards of directors of SWK Holdings Corp (NASDAQ:SWKH), Sincerus Pharmaceuticals, ExpressCells, II-VI, Inc. (NASDAQ: II-VI), Carmell Therapeutics, Syncardia Systems, and CannaPharma Rx (OTC: CPMD). She previously served as President and Chief Operating Officer of Camber Spine Technologies and has held Chief Financial Officer roles at Nuron Biotech, Quench USA, Globus Medical, and Kensey Nash Corporation. Her career started in public accounting at Deloitte & Touche in 1990. Ms. DiCicco received a B.S. in accounting from Philadelphia College of Textiles and Science and is a licensed CPA. She is also an appointed Board Leadership Fellow and Corporate Governance Fellow of the National Association of Corporate Directors (NACD).

We believe Ms. DiCicco is qualified to serve on our Board because of her highly successful career as a C-suite executive leading financial and operational organizations at numerous global, commercial-stage healthcare companies and her extensive strategic and financial expertise to expand commercial launch efforts.

Anthony P. Adamis, M.D.

Member of the Science Committee

Dr. Adamis has served as the co-founder and director for EyeBio, a privately held ophthalmology biotechnology company since August 2021, where he also has served as Chief Scientific Officer since 2022. Dr Adamis serves as director of Theia, a privately held ophthalmology biotechnology company since November 2021, as a director of Spiral, a privately held non-ophthalmic biotechnology company since October 2021 and as a director for RD Funds, the venture arm of the Foundation Fighting Blindness since October 2021.

 

Previously, Dr Adamis served as a director for Gyroscope Therapeutics Holdings plc, a clinical-stage gene therapy company focused on diseases of the eye from 2021 until its acquisition by Novartis in 2022. He has also served as Senior Vice President of Development Innovation at Genentech, now a wholly owned member of the Roche Group from 2018 to 2021. He is best known for his co-discovery of the central role of vascular endothelial growth factor (VEGF) in two leading causes of blindness: neovascular age-related macular degeneration (nAMD) and diabetic retinopathy. Conducted at Harvard in the 1990s, this research led to Dr. Adamis’ shared receipt of the Antonio Champalimaud Award, the highest honor in vision science, and to his election to the National Academy of Medicine. Over the course of his career, Dr. Adamis has helped develop 20 medicines across 30 indications, resulting in seven FDA Breakthrough Designations and 26 FDA approvals. Dr. Adamis received his M.D. from the University of Chicago, his ophthalmology training at the University of Michigan, and his fellowship training at Harvard University. He completed his research training in vascular biology with Judah Folkman, M.D., at Boston Children’s Hospital.

We believe Dr. Adamis is qualified to serve on the Board because of his extensive executive leadership experience, his extensive experience in ophthalmology, his extensive experience in the life sciences industry, and his service on the board of directors of other life sciences companies.

Karen Zaderej

Member of the Audit Committee

Ms. Zaderej has more than 35 years of biopharmaceutical and medical device experience. She currently serves as President, Chief Executive Officer, and Chair of the Board at Axogen (NASDAQ: AXGN). Earlier in her career, she held positions of increasing responsibility at Axogen, including Chief Operating Officer and Vice President of Marketing and Sales. Prior to joining Axogen in 2006, Ms. Zaderej worked for Zaderej Medical Consulting, a consulting firm she founded to assist medical device companies to build and execute successful commercialization plans. Previously, she worked at Ethicon, Inc., a Johnson & Johnson company, where she

11


 

held senior positions in marketing, business development, research & development, and manufacturing. Ms. Zaderej is a member of the Executive Committee and the Board of Trustees of the University of Tampa. She holds an M.B.A. from the Kellogg Graduate School of Business and a B.S. in Chemical Engineering from Purdue University.

 

We believe Ms. Zaderej is qualified to serve on the Board because of her extensive executive leadership experience, extensive experience in commercial development and her extensive experience at other life sciences companies.

Stuart Duty

Member of the Audit Committee

Stuart Duty is an experienced financial executive with over 30 years of experience in finance and investment banking. Mr. Duty has served as a director of Achieve Life Sciences, Inc. since March 2023.

 

Previously, Mr. Duty was a Senior Managing Director of Guggenheim Securities, LLC, a global investment, and advisory financial services firm, from June 2012 to March 2023. He also served as Managing Director, Co-Head, Healthcare Investment Banking at Piper Jaffray Companies, a global investment firm, from 2007 to 2012, as the Chief Operating Officer of Oracle Partners, L.P., a private healthcare focused investment fund, from 2002 to 2007, as Managing Director, Co-Head, Healthcare Investment Banking at Piper Jaffray, Inc., an global investment bank, from 1992 to 2002, as Managing Director, Healthcare Investment Banking at Montgomery Securities, an investment bank, from 1993 to 1999 and as the Director of Business Development at Curative Technologies, Inc., a biotherapeutics company, from 1992 to 1993. Mr. Duty holds a B.A. in Biochemistry from Occidental College and an M.B.A. from Harvard Business School.

We believe Mr. Duty is qualified to serve on the Board because of his extensive finance and investment banking experience, having guided numerous biotechnology and specialty pharmaceuticals companies through transactions and capital raise stages of growth.

Executive Officers

Each of our executive officers holds office until the first meeting of our Board following the next annual meeting of stockholders and until such officer’s respective successor is chosen and qualified, unless a shorter period shall have been specified by the terms of such officer’s election or appointment. The following table sets forth information about our executive officers as of April 23, 2024:

 

Name

 

Age

 

Position

Jay Duker, M.D.

 

65

 

President, Chief Executive Officer and Director

George Elston

 

59

 

Executive Vice President and Chief Financial Officer

Ramiro Ribeiro, M.D.

 

41

 

Chief Medical Officer

 

Jay Duker, M.D.

Please refer to the section entitled “Directors and Executive Officers – Directors and Director Nominees” above for Mr. Duker’s biographical information.

George Elston

Mr. Elston has served as our Executive Vice President and Chief Financial Officer since October 2023. From November 2019 to October 2023, Mr. Elston served as Chief Financial Officer. Mr. Elston brings more than 25 years of diverse financial and senior leadership experience in the biopharmaceutical sector with both global publicly-traded and privately-held organizations. Mr. Elston most recently served as Chief Financial Officer and Head of Corporate Development at Enzyvant Therapeutics from December 2018 to September 2019 where he helped build the pre-commercial rare disease firm leading to its recent 2019 acquisition. Before that, he was President and Chief Executive Officer at 2X Oncology, Inc. from May 2017 to October 2018, where he advanced the company from a spin-out into a multiprogram, clinical-stage organization. He was also SVP and CFO of Juniper Pharmaceuticals, Inc. from October 2014 to December 2016 and prior to that, held senior executive roles at KBI Biopharma, Inc., Optherion, Inc., Elusys Therapeutics, Inc. and CR Bard. Mr. Elston began his career in public accounting at Pricewaterhouse (now PricewaterhouseCoopers LLP). He earned his B.B.A. in accounting from Pace University and is a Certified Public Accountant. He currently serves as a Trustee and Audit Committee Chairman of the DWS – DBX ETF Trust.

12


 

Ramiro Ribeiro, M.D., PhD

Dr. Ribeiro has served as our Chief Medical Officer since March 2024, and was previously Vice President and Head of Clinical Development at Apellis Pharmaceuticals Inc. (NASDAQ: APLS) from 2018 to 2024. In his previous role, Dr. Ribeiro was responsible for building the pipeline strategy for Apellis’s ophthalmology franchise. He successfully led the cross-functional development team responsible for the global Phase 3 clinical program in Geographic Atrophy (GA) from protocol development through New Drug Application (NDA) submission and the U.S. FDA approval of SYFOVRE. Prior to joining Apellis in 2018, Dr. Ribeiro was the Senior Medical Director and Head of Digital Health at Acucela Inc., where he was responsible for multiple programs in retina. Previously, he held leadership roles at Ophthotech (Iveric Bio), Alcon (NYSE: ALC), Replenish, Inc., and 1Co Inc. Earlier, Dr. Ribeiro was a practicing retinal specialist. He holds a M.D. from Pontifical Catholic University and a Ph.D. in Stem Cell Therapy for Retinal Degenerative Diseases from the Federal University of São Paulo. He was also a research fellow at University of Southern California.

Family Relationships

There are no family relationships among any of our directors, director nominees or executive officers.

Arrangements between Officers, Directors and Director Nominees

Dr. Ando was initially appointed to the Board as the designee of EW Healthcare Partners, L.P. and EW Healthcare Partners-A, L.P. pursuant to the terms of a securities purchase agreement between us and the investors. The investors no longer have board nomination rights pursuant to such agreement.

Dr. Liu was initially appointed to the Board as the designee of Ocumension pursuant to the terms of a share purchase agreement between us and Ocumension. Ocumension no longer has board nomination rights pursuant to such agreement.

Other than as disclosed above, there is no arrangement or understanding between any of our executive officers, directors or director nominees and any other person, pursuant to which such person was selected to serve as an executive officer or director, as applicable.

CORPORATE GOVERNANCE AND BOARD MATTERS

Director Independence

The Board has unanimously determined that Dr. Ando, Dr. Guyer, Ms. DiCicco, Dr. Adamis, Ms. Zaderej, and Mr. Duty are independent under applicable standards of the SEC and Nasdaq. Dr. Duker does not qualify as independent due to the fact that Dr. Duker serves as President and Chief Executive Officer of the Company. Ms. Lurker does not qualify as independent due to the fact that she serves as the Executive Vice Chair of the Board and previously served as President and Chief Executive Officer of the Company. Our Board determined that Dr. Landis does not qualify as independent due to the fact that he currently serves as a consultant to EyePoint leading the Company GMP process.

Each of the Audit Committee, the Compensation Committee and the Governance and Nominating Committee is comprised entirely of independent directors. Other than Dr. Landis, the Science Committee is also comprised of independent directors.

Board Leadership Structure, Processes, and Role in Risk Oversight

Board Leadership Structure

The Board has chosen to separate the roles of Board Chair and Chief Executive Officer and believes that such a separation of roles is in our best interests and the best interests of our stockholders. Dr. Ando's extensive experience in the life sciences industry in both senior management and board of director positions coupled with his perspective as an independent director provide effective leadership for our Board and support for our executive team. The leadership structure also includes an Executive Vice Chair to the Board of Directors. Ms. Lurker's broad ranging experience in leading the Company and her track record of maximizing the potential of new therapies with over ten years of clinical drug development experience as a senior executive, and successfully implementing innovative U.S. and global drug launches, provide her with valuable expertise to provide leadership for our Board and support of the executive team.

13


 

Board’s Role in Risk Oversight

It is management’s responsibility to manage risk and bring to the Board’s attention risks that are material to the Company. The Board has oversight responsibility for the systems established to report and monitor the most significant risks applicable to us. The Board administers its risk oversight role directly and through its committee structure. The Board reviews strategic and financial risks and exposures associated with our long-term strategy, development, and commercialization of products and product candidates and other matters that may present material risk to our operations, strategy, and prospects. The Audit Committee reviews risks associated with financial and accounting matters, including financial reporting, accounting, disclosure and internal control over financial reporting, as well as overall risk assessment and management, including risks associated with information technology (cybersecurity) and compliance (including healthcare and related regulatory matters). The Compensation Committee reviews risks related to executive compensation and the design of compensation programs, plans and arrangements, as well as risks and overall approach related to human capital matters, including diversity and inclusion, employee engagement, and culture. The Governance and Nominating Committee manages risks associated with corporate governance, as well as Board composition and procedures. The Science Committee supports the Board’s oversight of risks related to our research and development (R&D) organization.

Executive Sessions

Executive sessions of our independent directors are held at each regularly scheduled meeting of our Board and at other times they deem necessary. Our Board’s policy is to hold executive sessions both with and without the presence of management. Our Board committees also generally meet in executive session at the end of each committee meeting.

Executive and Director Compensation Processes

The agenda for each meeting of the Compensation Committee is usually developed by the Chair of the Compensation Committee in consultation with our Chief Executive Officer. The Compensation Committee meets regularly in executive session. From time to time, various members of management and other employees as well as outside advisors or consultants may be invited by the Compensation Committee to make presentations, to provide financial or other background information or advice, or to otherwise participate in Compensation Committee meetings. No officer may participate in, or be present during, any deliberations or determinations of the Compensation Committee regarding the compensation for such officer or employee. Our Chief Executive Officer provides recommendations to our Compensation Committee with respect to executive and employee compensation, other than his own compensation. The Compensation Committee takes into consideration Dr. Duker’s input in granting annual bonuses or equity awards and setting compensation levels.

The charter of the Compensation Committee grants the Compensation Committee full access to all of our books, records, facilities, and personnel, as well as the authority to obtain, at our expense, advice and assistance from internal and external legal, accounting, or other advisors and consultants and other external resources that the Compensation Committee considers necessary or appropriate in the performance of its duties. In particular, the Compensation Committee has the authority to retain compensation consultants to assist in its evaluation of executive and director compensation, including the authority to approve the consultant’s reasonable fees and other retention terms.

During 2023, the Compensation Committee retained Aon’s Human Capital Solutions practice, a division of Aon, plc (Aon), as its independent consultant to assist in evaluating our executive compensation programs and practices and to make recommendations regarding compensation for the year ended December 31, 2023. During this process, Aon:

prepared competitive market data for the compensation of our executive management team;
evaluated the continued appropriateness of and made recommendations regarding our peer group;
analyzed our short term and long-term incentive plan designs and made recommendations in connection therewith;
reviewed equity retention and our equity burn rate and dilution levels relative to the market;
assessed our compensation practices and levels against those of our peer group companies and the broader marketplace;
made recommendations regarding base salary, target bonus percentage and long-term incentive compensation for each Named Executive Officer; and
updated the Compensation Committee on compensation trends and regulatory developments.

None of Aon or their affiliates provides other services to us. The Compensation Committee assessed the independence of Aon pursuant to SEC rules and concluded that no conflict of interest existed that would prevent Aon from independently representing the

14


 

Compensation Committee. The Compensation Committee has sole responsibility for the selection, engagement, removal and compensation of its compensation consultant.

The Compensation Committee may form and delegate any or all of its duties or responsibilities to a subcommittee of the Compensation Committee, to the extent consistent with our Certificate of Incorporation, bylaws and applicable laws and rules of markets in which our securities then trade.

Board Committees

The Board has four standing committees: the Audit Committee, the Compensation Committee, the Governance and Nominating Committee and the Science Committee. Each standing committee has a written charter. Each of the Audit Committee, the Compensation Committee and the Governance and Nominating Committee is comprised entirely of independent directors. The Science Committee is currently comprised of independent directors and Dr John Landis, who serves as both a consultant leading the Company GMP and also as a Board member; however, it may also in the future include members of our R&D organization and other members of executive management in accordance with its charter. While each committee has designated responsibilities, the committees act on behalf of the entire Board and regularly report on their activities to the entire Board. Details concerning the role and structure of the Board and each Board committee are contained in the Corporate Governance Guidelines and the committee charters, available on the “Investor” section of our website at www.eyepointpharma.com under “Corporate Governance.”

Audit Committee

The Audit Committee is responsible for assisting the Board with oversight of our accounting and financial reporting processes, including but not limited to (a) our audit program; (b) the integrity of our financial statements; (c) the review and assessment of the qualifications and independence of our independent registered public accounting firm; and (d) the preparation of reports required of the Audit Committee under the rules of the SEC. The Audit Committee is also responsible for (i) overseeing the establishment of effective internal controls and procedures intended to ensure the Company’s compliance with relevant accounting standards, financial reporting procedures and applicable laws and regulations, (ii) overseeing and monitoring the Company’s compliance with legal and regulatory requirements, and (iii) overseeing the Company’s risk assessment and risk management policies and programs, including matters relating to cybersecurity.

 

More specifically, the Audit Committee’s responsibilities include:

appointing, overseeing and, if necessary, replacing the independent registered public accounting firm, including evaluating the effectiveness and independence of the firm at least annually, reviewing and evaluating the lead partner of the firm and ensuring the lead partner is rotated at least every five years, approving or pre-approving all audit and non-audit services provided by the firm and establishing hiring policies for employees or former employees of the firm, and also including resolving any disagreements between management and the firm regarding financial reporting;
reviewing with the independent registered public accounting firm the scope of, plans for and any difficulties with audits and the adequacy of staffing and compensation;
reviewing with the independent registered public accounting firm matters required to be communicated to audit committees in accordance with Public Company Accounting Oversight Board (PCAOB) Auditing Standard No. 1301, Communications with Audit Committees;
reviewing with management and the independent registered public accounting firm our internal controls, financial and critical accounting policies (including effects of alternate United States generally accepted accounting principles (GAAP) methods and off-balance sheet structures, if any) and significant judgments;
reviewing with management and the independent registered public accounting firm our annual and quarterly financial statements and financial disclosure, and preparing the Audit Committee report for inclusion in our annual proxy statement;
reviewing, or establishing standards for, the substance and presentation of information included in earnings press releases and other earnings guidance;
reviewing material pending legal proceedings and other contingent liabilities;
implementing appropriate control processes for accounting, disclosures and reporting, review and approval of intracompany, related party, and significant unusual transactions;
establishing procedures for receipt, retention and treatment of complaints, including the confidential and anonymous submission of concerns by employees regarding accounting, internal accounting controls or auditing matters;

15


 

reviewing with management and the independent registered public accounting firm any identified significant deficiencies and material weaknesses in the design or operation of our internal controls, and any allegation of fraud involving management or other employees who have a significant role in our internal controls;
overseeing our policies with respect to risk assessment and risk management and periodically discussing our plans or processes to monitor, control and minimize corporate risks and exposures with respect to information technology and cybersecurity with our external legal counsel, insurance advisors, external cyber security consultants, and the independent registered public accounting firm;
overseeing and monitoring our compliance programs, including the design and implementation of appropriate compliance programs, policies and procedures, and the management of matters involving significant legal or regulatory compliance exposure or material reports or inquiries from government or regulatory agencies;
preparing a report for inclusion in our annual proxy statement as required by the SEC;
presenting to the Board annually an evaluation of the Audit Committee’s performance and charter; and
performing such other activities as the Board or the Audit Committee deem appropriate.

The members of the Audit Committee are Ms. DiCicco (Chair), Dr. Guyer, Ms. Zaderej and Mr. Duty. Ms. DiCicco, Dr. Guyer, Ms. Zaderej, and Mr. Duty were members of the Audit Committee during the year ended December 31, 2023.

The Board has determined that all members of the Audit Committee are independent for purposes of service on the Audit Committee as provided in SEC and Nasdaq rules, as applicable. The Board also has determined that Ms. DiCicco, Dr. Guyer, Ms. Zaderej, and Mr. Duty are "audit committee financial experts" as defined under SEC rules.

The Audit Committee met five times during the year ended December 31, 2023.

Compensation Committee

The Compensation Committee is responsible for (i) discharging the Board’s responsibilities relating to executive compensation, (ii) overseeing our compensation and employee benefits plans and practices, including incentive, equity-based and other compensatory plans in which executive officers and key employees participate, (iii) producing a report on executive compensation as required by the SEC, and (iv) overseeing our approach and management of risks related to human capital. More specifically, the Compensation Committee’s responsibilities include, but are not limited to:

developing and periodically reviewing compensation policies and practices applicable to executive officers;
determining and approving the compensation of the Chief Executive Officer (CEO) and other executive officers;
supervising, administering, and evaluating incentive, equity-based, and other compensatory plans of our company in which executive officers and key employees participate, including approving guidelines and size of grants and awards, making grants and awards, interpreting and promulgating rules relating to the plans, modifying or canceling grants or awards, designating employees eligible to participate, and imposing limitations and conditions on grants or awards;
overseeing our policies on structuring compensation programs to preserve tax deductibility, and, when required, establish performance goals and certify that performance goals have been attained;
reviewing and making recommendations to the Board regarding any executive and equity compensation plans and such other compensation and benefit plans that are subject to Board approval and, where appropriate or required, to stockholder approval;
approving any tax-qualified, non-discriminatory employee benefit plans (and any parallel nonqualified plans) for which stockholder approval is not sought and pursuant to which options or stock may be acquired by our officers, directors, employees or consultants;
reviewing and approving any employment agreements, severance arrangements, change-in-control arrangements or special or supplemental employee benefits, and any material amendments to any of the foregoing, applicable to executive officers;
making individual determinations and granting any shares, stock options, or other equity-based awards under all equity-based compensation plans that are outside approved guidelines for such grants, and exercising such power and authority as may be required or permitted under such plans;

16


 

determining stock ownership guidelines, if any for the CEO and other executive officers and non-employee directors and monitor compliance;
reporting to the Board on any significant matters arising from the Committee’s work;
annually evaluating the performance of the Compensation Committee and presenting results to the Board;
annually reviewing and reassessing the charter of the Compensation Committee and, if appropriate, recommending changes to the Board;
annually evaluating the adequacy of directors’ compensation and the composition of such compensation;
reviewing the Compensation Discussion & Analysis to be included in our annual proxy statement or Annual Report on Form 10-K and issuing a Compensation Committee report thereon as required by the SEC to be included in our annual proxy statement or Annual Report on Form 10-K filed with the SEC;
reviewing risks that we may face as a result of our compensation policies and practices and assess whether such policies and practices are reasonably likely to have a material adverse effect and implement appropriate means to mitigate these risks;
periodically review and revise a peer group of companies against which to assess our compensation programs and practices to ensure they are competitive and supportive of our strategy and objectives;
approving and overseeing the application of our policy for clawback, or recoupment, of incentive compensation;
overseeing engagement with stockholders and proxy advisory firms on executive compensation matters;
overseeing the Company’s management of risks and overall approach related to human capital matters, including diversity and inclusion, employee engagement, and culture;
annually or during a time frame required by law or the Company's bylaws reviewing and recommending to the Board for approval of, (i) the frequency with which we conduct stockholder advisory votes on executive compensation (Say on Pay Vote) and (ii) any proposals related to the Say on Pay Vote to be included in our annual proxy statement, in each case as applicable;
performing such other duties and responsibilities as may be assigned to the Compensation Committee by the Board or as designated in plan documents;
periodically review and make recommendations to the Board relating to senior executive succession planning, including policies and principles for CEO selection and performance review, as well as policies regarding succession in the event of an emergency or the retirement of the CEO or other executive officer; and,
forming and delegating authority to subcommittees, comprised of one or more members of the Compensation Committee, when the Compensation Committee deems appropriate.

The members of the Compensation Committee are Dr. Guyer (Chair), Dr. Ando, and Ms. DiCicco. Dr. Guyer, Dr. Ando, and Ms. DiCicco were members of the committee during the year ended December 31, 2023.

The Board has determined that all members of the Compensation Committee are independent for purposes of service on the Compensation Committee as provided in SEC and Nasdaq rules, as applicable.

The Compensation Committee met four times during the year ended December 31, 2023.

The processes and procedures followed by our Compensation Committee in considering and determining executive and director compensation are described above under “Corporate Governance and Board Matters—Board Leadership Structure, Processes, and Role in Risk Oversight—Executive and Director Compensation Processes.”

Governance and Nominating Committee

The Governance and Nominating Committee is responsible for (i) identifying and recommending to the Board individuals qualified to serve as directors and advising the Board with respect to Board composition and procedures, (ii) overseeing the evaluation of the Board and the committees, (iii) developing and maintaining our corporate governance policies, and (iv) overseeing our activities relating to corporate social responsibility and environmental and sustainability matters. The Governance and Nominating Committee has periodically engaged third parties to identify and evaluate candidates qualified to serve as our directors and may continue to do so in the future. More specifically, the Governance and Nominating Committee’s responsibilities include:

17


 

identifying, recruiting and interviewing candidates for Board membership;
reviewing the background and qualifications of individuals being considered as director candidates;
developing and recommending to the Board guidelines and criteria to determine the qualifications, qualities, skills, and other expertise of directors, which reflect the Board’s commitment to actively develop a diverse pool of individuals from which director nominees may be selected;
recommending to the Board the director nominees for election by the stockholders or appointment by the Board to fill any vacancies pursuant to our bylaws;
reviewing and considering candidates for election submitted by stockholders;
reviewing the suitability for continued service as a director of each Board member when his or her term expires, and recommending whether or not the director should be re-nominated;
monitoring the independence (within the meaning of the Nasdaq listing requirements) of Board members and the overall Board composition;
reviewing periodically the size of the Board and to recommend to the Board any appropriate changes;
making recommendations on the frequency and structure of Board meetings and on the practices of the Board;
making recommendations concerning any other aspect of the procedures of the Board that the Committee considers warranted;
recommending to the Board the directors to be appointed to each committee of the Board, including the Governance and Nominating Committee;
recommending to the Board the director to serve as Chair of the Board and the directors to serve as Chair of each committee of the Board, including the Governance and Nominating Committee;
overseeing an orientation program for new Board members and continuing education for all Board members;
reviewing our corporate governance practices, including identifying best practices, reviewing information regarding the operations of the committees of the Board, director independence, the director nominations process and the documents, policies and procedures in our corporate governance framework on a periodic basis but at least annually, and discussing the results with management, making recommendations relative to the nature of the corporate governance disclosure that should be included in our proxy statement or annual report on Form 10-K, as applicable;
overseeing an annual self-evaluation of the Board and its committees to determine whether the Board and its committees are functioning effectively;
annually evaluating the Committee’s performance;
annually reviewing and assessing the adequacy of the Governance and Nominating Committee Charter and recommending any proposed changes to the Board for approval;
developing and recommending to the Board a set of corporate governance guidelines applicable to us;
overseeing, reviewing and discussing with management and the Board, and making recommendation to the Board regarding our policies, goals and initiatives relating to corporate social responsibility and environmental and sustainability matters, and the external reporting thereof;
performing such other duties and responsibilities as may be assigned to the Governance and Nominating Committee by the Board or as designated in plan documents; and
forming and delegating authority to subcommittees, comprised of one or more members of the Governance and Nominating Committee, when the Governance and Nominating Committee deems appropriate.

The members of the Governance and Nominating Committee are Dr. Ando (Chair), Ms. DiCicco, and Dr. Guyer. Each of Dr. Ando, Ms. DiCicco, and Dr. Guyer was a member of the committee during the year ended December 31, 2023.

The Board has determined that all members of the Governance and Nominating Committee are independent for purposes of service on the Governance and Nominating Committee as provided in SEC and Nasdaq rules, as applicable.

The Governance and Nominating Committee met four times during the year ended December 31, 2023.

18


 

Science Committee

The Science Committee is responsible for assisting the Board in ensuring that our research and development organization is optimized to support the strategic goals and making recommendations to the Board on key strategic and tactical issues relating to our research and development activities. To accomplish this purpose, the Committee reviews and monitors the science, processes, procedures, and infrastructure underlying the Company’s major discovery and development programs. More specifically, the Science Committee’s responsibilities include:

reviewing the science and clinical and regulatory strategy underlying the major research and development programs, including publication strategies;
reviewing our significant medical affairs strategies and initiatives;
reviewing the annual research and development budget and allocation of resources to discovery and development programs;
reviewing the capacity and skill set of the research and development organization;
reviewing the implications for the research and development organization of significant business development transactions, including mergers, acquisitions, licensing, and collaborative agreements;
reviewing the progress toward achievement of key research and development milestones;
reviewing the interactions of the research and development organization with health care providers and regulatory bodies, especially with regard to the reporting of adverse events and/or unexpected negative data observed in the preclinical and clinical studies conducted by us;
retaining, as necessary, the services of one or more advisors, consultants, or attorneys, which may be our in-house or outside counsel, to assist the Science Committee in discharging its responsibilities under the Science Committee Charter; and
forming and delegating authority to subcommittees, comprised of one or more members of the Science Committee, when the Science Committee deems appropriate.

The current members of the Science Committee are Dr. Landis (Chair), Dr. Ando, Dr. Guyer, and Dr. Adamis. Each of Dr. Landis, Dr. Ando, Dr. Guyer, and Dr. Adamis was a member of the committee during the year ended December 31, 2023.

The Science Committee met four times during the year ended December 31, 2023.

Attendance at Board and Committee Meetings

The Board met four times during the year ended December 31, 2023. Except for Mr. Liu, each of the directors who served during the year ended December 31, 2023 are standing for election in 2024. Each of the directors who served the full year attended at least 75% of the aggregate of the total number of meetings of the Board and of the committees on which he or she served (during the period that each such director served). Our corporate governance guidelines encourage, but do not require our directors to attend annual meetings of stockholders. All but one of the directors who was serving as a director as of the 2023 Annual Meeting attended the 2023 Annual Meeting, either in person or by telephone.

Stockholder Nominations for Director

The Governance and Nominating Committee will consider written stockholder recommendations for candidates for the Board, which recommendations should be delivered or mailed, postage prepaid, to:

Company Secretary

EyePoint Pharmaceuticals, Inc.

480 Pleasant Street, Suite C400

Watertown, MA 02472

United States

Stockholder recommendations must include certain relevant information concerning the candidate, the stockholder making the recommendation and any beneficial owner on whose behalf the recommendation is made. The required information is set forth in our

19


 

Stockholder Nomination Policy, available on the “Investor” section of our website at www.eyepointpharma.com under “Corporate Governance – Governance Overview.”

The Governance and Nominating Committee will evaluate candidates for director who are recommended by stockholders on the same basis as candidates recommended by other sources. Considerations include the Governance and Nominating Committee’s discretionary assessment of the skills represented and required on the Board, and an evaluation of candidates against the standards and qualifications set forth in our Corporate Governance Guidelines and criteria approved by the Board from time to time. We do not have a formal policy with respect to diversity, although we seek to have a Board that reflects a range of talents, ages, skills, viewpoints, professional experience, educational backgrounds, expertise, genders, and ethnicities. The Governance and Nominating Committee will determine whether to interview any candidate in its sole discretion.

Stockholder Communications with Directors

Stockholders and other interested parties may communicate directly with the Board, the independent directors, the Chair of the Board, any other group of directors or any individual director. The required information is set forth in our Policy Regarding Stockholder Communications With Directors, available on the “Investor” section of our website at www.eyepointpharma.com under “Corporate Governance – Governance Overview.” Any such written communications should be addressed to the relevant group or individual and sent to the following address:

Name(s) of Director(s), Group of Directors or Board of Directors

c/o Company Secretary

EyePoint Pharmaceuticals, Inc.

480 Pleasant Street, Suite C400

Watertown, MA 02472

United States

Our Company Secretary will forward such communications to the relevant group or individual at or prior to the next meeting of the Board.

Code of Business Conduct

We have adopted a Code of Business Conduct applicable to each of our officers, directors and employees, and consultants and contractors to, us and our subsidiaries, including our principal executive officer and principal financial officer. The Code of Business Conduct is a set of policies on key integrity issues that requires our representatives to act ethically and legally. It includes policies with respect to conflicts of interest, corporate & social responsibility, compliance with laws, insider trading, corporate opportunities, competition and fair dealing, discrimination and harassment, health and safety, record-keeping, confidentiality, protection and proper use of assets, payments to government personnel, and reports to and communications with the SEC and the public.

We review the Code of Conduct annually and update it as appropriate. We intend to disclose any future amendments to, or waivers from, the Code of Business Conduct that affect our directors or senior financial and executive officers within four business days of the amendment or waiver by posting such information on the “Investor” section of our website at www.eyepointpharma.com under “Corporate Governance—Governance Overview.”

Insider Trading, Hedging and Pledging Prohibition

Under our Insider Trading Policy, our directors, officers, employees, consultants, and contractors (and each such individual’s family members who reside with them, anyone else who lives in their household and any family members who do not live in their household but whose transactions in our securities are directed by the insider or are subject to the insider’s influence or control) are prohibited from engaging the following transactions at any time: (i) engaging in short sales of our securities; (ii) trading in put options, call options or other derivative securities on an exchange or in any other organized market; (iii) engaging in hedging or monetization transactions, including through the use of financial instruments such as prepaid variable forwards, equity swaps, collars and exchange funds; and (iv) holding our securities in a margin account or otherwise pledging our securities as collateral for loan. Our full insider trading policy is on our website, www.eyepointpharma.com. The information contained on the Company's website is not deemed incorporated by reference in this proxy statement.

Audit Committee Report

As more fully described in its charter, the Audit Committee oversees our financial reporting process on behalf of the Board. Our management is responsible for our financial reporting process, including assuring that we develop and maintain adequate financial

20


 

controls and procedures, and assess compliance therewith. Our independent registered public accounting firm, Deloitte & Touche LLP (Deloitte) is responsible for performing an audit of the effectiveness of our internal control over financial reporting in conjunction with an audit of our consolidated financial statements in accordance with standards of the Public Company Accounting Oversight Board (United States) (PCAOB), and issuing its opinion on the financial statements and the effectiveness of internal control over financial reporting.

The Audit Committee reviewed and discussed our audited consolidated financial statements for the fiscal year ended December 31, 2023 with our management and Deloitte. The Audit Committee also reviewed and discussed with Deloitte our audited consolidated financial statements and the matters required to be discussed by the applicable requirements of the PCAOB. The Audit Committee met with Deloitte, with and without management present, to discuss the results of their examinations, other areas of oversight relating to the financial reporting and audit process that the Audit Committee determined appropriate, their evaluation of our internal controls, and the overall quality of our financial reporting.

The Audit Committee discussed with Deloitte the firm’s independence and received from Deloitte and reviewed the written disclosures and the letter required by PCAOB Ethics and Independence Rule 3526 (Communication with Audit Committees Concerning Independence). The Audit Committee considered whether Deloitte’s provision of non-audit services to us is compatible with Deloitte’s independence and concluded that Deloitte is independent from our company and our management.

Based on the above-referenced reviews and discussions with our management and Deloitte, the Audit Committee recommended to the Board that our audited consolidated financial statements be included in our Annual Report on Form 10-K for the year ended December 31, 2023, for filing with the SEC.

 

 

Submitted by the members of the

 

Audit Committee

 

 

Wendy DiCicco (Chair)

 

David Guyer

 

Karen Zaderej

 

Stuart Duty

 

RELATED PARTY TRANSACTIONS

Policy Regarding Transactions with Related Persons

We maintain a written "Related Party Transaction Policy.” Under this policy, the Audit Committee or, in time sensitive instances, the Chair of the Audit Committee, has responsibility for reviewing and approving or ratifying any transaction in which we and any of our directors, director nominees, executive officers or 5% stockholders and their immediate family members are participants, or in which such persons have a direct or indirect material interest, as provided under SEC rules. In reviewing transactions, the committee or the Chair considers all of the relevant facts and circumstances, and approves only those transactions that the committee or the Chair in good faith determines to be in, or not inconsistent with, the best interests of us and our stockholders. Except as otherwise disclosed below, there were no such related-person transactions since January 1, 2022.

Transactions with Related Persons

Ocumension Transactions

Licensing Transactions

In November 2018, we entered into an exclusive license agreement with Ocumension for the development and commercialization of our three-year micro insert using the Durasert® technology for the treatment of chronic non-infectious uveitis affecting the posterior segment of the eye (YUTIQ in the U.S.) in Mainland China, Hong Kong, Macau, and Taiwan.

In August 2020, we entered into a Memorandum of Understanding (2020 MOU) pursuant to which we received a one-time non-refundable payment of $9.5 million (Accelerated Milestone Payment) from Ocumension as a full and final payment of the combined remaining development, regulatory, and sales milestone payments under our license agreements with Ocumension for the treatment of

21


 

chronic non-infectious uveitis affecting the posterior segment of the eye and for the treatment of post-operative inflammation following ocular surgery. Upon payment of the Accelerated Milestone Payment, the remaining $11.75 million in combined remaining development and sales milestone payments under our original license agreement with Ocumension upon the achievement by Ocumension of (i) remaining development and regulatory milestones of $6.25 million and commercial sales-based milestones of $3.0 million for the development and commercialization of our three-year micro insert using the Durasert technology for the treatment of chronic non-infectious uveitis affecting the posterior segment of the eye; and (ii) $6.0 million upon the achievement by Ocumension of certain prescribed development and regulatory milestones, and $6.0 million commercial sales-based milestones for the development and commercialization in Mainland China, Hong Kong, Macau and Taiwan of DEXYCU® for the treatment of post-operative inflammation following ocular surgery, totaling up to $21.25 million, were permanently extinguished and will no longer be due to us. In exchange, Ocumension also received exclusive rights to develop and commercialize YUTIQ® and DEXYCU products under its own brand names in South Korea and other jurisdictions across Southeast Asia in Brunei, Burma (Myanmar), Cambodia, Timor-Leste, Indonesia, Laos, Malaysia, the Philippines, Singapore, Thailand, and Vietnam, at its own cost and expense with us supplying product for clinical trials and commercial sale.

YUTIQ received regulatory approval in China in June 2022, and is now being marketed and sold commercially by Ocumension in China. Pursuant to our agreements with Ocumension, we are entitled to receive mid-single digit sales-based royalties on their net sales of YUTIQ.

Other than a fixed number of hours of technical assistance support to be provided at no cost by us, Ocumension is responsible for all development, regulatory and commercial costs, including any additional technical assistance requested.

Director and Officer Indemnification Agreements

We have entered into indemnification agreements with our directors and executive officers. In general, these agreements provide that we will indemnify the director or executive officer to the fullest extent permitted by law for claims arising in his or her capacity as a director or executive officer of our company or in connection with their service at our request for another corporation or entity. The indemnification agreements also provide for procedures that will apply in the event that a director or executive officer makes a claim for indemnification and establishes certain presumptions that are favorable to the director or executive officer.

We maintain a general liability insurance policy that covers certain liabilities of our directors and officers arising out of claims based on acts or omissions in their capacities as directors or officers.

 

STOCK OWNERSHIP

Stock Ownership of Directors, Director Nominees, Officers and Principal Stockholders

At the close of business on April 23, 2024, there were 52,084,148 shares of our common stock issued and outstanding and entitled to vote. On April 23, 2024, the closing price of our common stock as reported on the Nasdaq Global Market was $17.57 per share. The following table sets forth certain information relating to the beneficial ownership of our common stock as of April 23, 2024 by:

each person, or group of affiliated persons, known by us to beneficially own more than 5% of our outstanding shares of common stock;
each of our current directors and director nominees;
each of our Named Executive Officers (as defined below); and
all of our current directors and executive officers as a group.

Beneficial ownership is determined in accordance with the rules of the SEC as indicated in the footnotes to the table below.

Unless otherwise indicated, the address for each of the beneficial owners listed below is: c/o EyePoint Pharmaceuticals, Inc., 480 Pleasant Street, Suite C400, Watertown, MA 02472, United States.

 

22


 

Beneficial Owner

 

Aggregate
Number of
Shares Beneficially
Owned
(1)

 

 

Percent of
Shares
Beneficially
Owned

 

Greater Than 5% Stockholder:

 

 

 

 

 

 

Cormorant Asset Management(2)

 

 

7,475,000

 

 

 

14.35

%

Adage Capital(3)

 

 

5,156,299

 

 

 

9.90

%

Suvretta Capital Management(4)

 

 

5,147,756

 

 

 

9.68

%

Franklin Resources(5)

 

 

4,640,651

 

 

 

8.91

%

RA Capital Management(6)

 

 

3,095,136

 

 

 

5.94

%

Executive Officers and Directors:

 

 

 

 

 

 

Göran Ando

 

 

91,100

 

 

*

 

Jay Duker(7)

 

 

434,137

 

 

*

 

Nancy Lurker(8)

 

 

1,018,781

 

 

 

1.93

%

John Landis

 

 

87,850

 

 

*

 

David Guyer

 

 

79,850

 

 

*

 

Wendy DiCicco

 

 

79,850

 

 

*

 

Ye Liu(9)

 

 

100,221

 

 

*

 

Anthony P. Adamis

 

 

48,433

 

 

*

 

Karen Zaderej

 

 

48,433

 

 

*

 

George Elston

 

 

271,438

 

 

*

 

Dario Paggiarino(10)

 

 

304,894

 

 

*

 

Stuart Duty

 

 

 

 

*

 

All current directors and executive officers
   as a group (12 persons)
(11)

 

 

2,564,987

 

 

 

4.74

%

* Represents holdings of less than 1% of our outstanding common stock.

(1)
Reflects sole voting and investment power, except as indicated below. Includes shares of common stock that each of the following persons had the right to acquire on April 23, 2024 or within sixty (60) days thereafter through the exercise of stock options or vesting and settlement of restricted stock units: Dr. Ando (82,950), Dr. Duker (382,217), Ms. Lurker (808,541), Dr. Landis (76,450), Dr. Guyer (72,450), Ms. DiCicco (72,450), Mr. Elston (227,831), and Dr. Paggiarino (237,814).
(2)
As of April 18, 2024, based on information set forth in a Statement of Beneficial Ownership on Schedule Form 4 filed with the SEC on April 22, 2024 by Cormorant Asset Management, LP(“Cormorant”), Bihua Chen and Cormorant Global Healthcare Master Fund, LP (the “Master Fund”) with a business address of 200 Clarendon Street, 52nd Floor, Boston, MA 02116. Cormorant serves as the investment manager of the Master Fund. Cormorant Global Healthcare GP, LLC ("GP LLC") serves as General Partner of the Master Fund. Bihua Chen serves as manager of Cormorant, GP LLC.
(3)
As of April 18, 2024, based on information set forth in a Statement of Beneficial Ownership on Schedule Form 3 filed with the SEC on April 22, 2024 by Adage Capital Management, L.P., Robert Atchinson and Phillip Gross, with a business address of 200 Clarendon Street, 52nd Floor, Boston, Massachusetts 02116. The securities are held directly by Adage Capital Partners, L.P., a Delaware limited partnership ("ACP"). Adage Capital Management, L.P., a Delaware limited partnership ("ACM"), serves as the investment manager of ACP and as such has discretion over the portfolio securities held by ACP. Robert Atchinson and Phillip Gross are the managing members of (i) Adage Capital Advisors, L.L.C., a Delaware limited liability company, managing member of Adage Capital Partners GP, L.L.C., a Delaware limited liability company, general partner of ACP and (ii) Adage Capital Partners LLC, a Delaware limited liability company, general partner of ACM.
(4)
As of December 31, 2023, based on information set forth in a Schedule 13G/A filed with the SEC on February 13, 2024 by Suvretta Capital Management, LLC (Suvretta), with a business address of 540 Madison Avenue, 7th Floor, New York, NY 10022. Shares of common stock directly held by Averill Master Fund, Ltd. (the “Fund”), with a business address of c/o Maples Corporate Services Limited P.O. Box 309 Ugland House Grand Cayman KY1-1104 Cayman Islands, may be deemed to be indirectly beneficially owned by Suvretta Capital Management, LLC and Aaron Cowen. Aaron Cowen has beneficial ownership by virtue of his role as a control person of Suvretta Capital Management, LLC. The shares reflected as beneficially owned by Suvretta in the table above consist of (i) 4,056,847 shares of common stock and (ii) warrants to purchase 1,090,909 shares of common stock.
(5)
As of December 31, 2023, based on information set forth in a Schedule 13G/A filed with the SEC on February 6, 2024 by Franklin Resources Inc., Charles B. Johnson, Rupert H. Johnson, Jr. and Franklin Advisers, Inc., with a business address of One Franklin Parkway, San Mateo, CA 94403.

23


 

(6)
As of December 31, 2023, based on information set forth in a Schedule 13G/A filed with the SEC on February 14, 2024 by RA Capital Management, L.P. (RA Capital), with a business address of 200 Berkeley Street, 18th Floor, Boston, MA 02116. The shares reflected as beneficially owned by RA Capital in the table above consist of (i) 913,318 shares of common stock and (ii) warrants to purchase 2,181,818 shares of common stock. On April 18, 2024, RA Capital exercised their warrants in full via a cashless exercise resulting in the net shares issuance of 2,180,776 shares. RA Capital Healthcare Fund GP, LLC is the general partner of RA Capital Healthcare Fund, L.P. (the “Fund”). The general partner of RA Capital is RA Capital Management GP, LLC, of which Dr. Peter Kolchinsky and Mr. Rajeev Shah are the controlling persons. RA Capital serves as investment adviser for the Fund and may be deemed a beneficial owner, for purposes of Section 13(d) of the Securities Exchange Act of 1934 (the “Act”), of any securities of the Company held by the Fund. The Fund has delegated to RA Capital the sole power to vote and the sole power to dispose of all securities held in the Fund’s portfolio, including the shares of the Company’s common stock reported therein. As managers of RA Capital, Dr. Kolchinsky and Mr. Shah may be deemed beneficial owners, for purposes of Section 13(d) of the Act, of any securities of the Company beneficially owned by RA Capital.
(7)
Includes 22,500 shares of common stock that were transferred to an irrevocable family trust of which Dr. Duker's spouse is trustee and of which Dr. Duker's immediate family members are the sole beneficiaries.
(8)
Includes 126,889 shares of common stock and 712,764 non-qualified vested stock options that were transferred to an irrevocable family trust of which Ms. Lurker’s spouse is trustee and of which Ms. Lurker’s immediate family members are the sole beneficiaries.
(9)
Based, in part, on information provided on a Statement of Beneficial Ownership on Form 4 filed on January 16, 2024 by Ocumension Therapeutics. Mr. Liu is a member of EyePoint’s Board of Directors. Ocumension’s business address is 56F, One Museum Place, 669 Xin Zha Road, Jing’an District, Shanghai F4 200041.
(10)
Reflects Dr. Paggiarino’s holdings as of March 29, 2024 which was his last day of employment with the Company.
(11)
Also included in the shares beneficially owned by all current directors and executive officers as a group is the following: shares of common stock that each had the right to acquire on April 23, 2024 or within sixty (60) days thereafter through the exercise of stock options: Mr. Ribiero (none).

Equity Compensation Plan Information

The following table provides information about the securities authorized for issuance under the Company’s equity compensation plans as of December 31, 2023:

 

Plan category

 

Number of securities
to be issued upon
exercise of
outstanding
options, warrants
and rights
(a)

 

Weighted-average
exercise price of
outstanding
options, warrants
and rights
(b)
(4)

 

Number of securities
remaining available
for future issuance
under equity
compensation plans
(excluding securities
reflected in Column a)
(c)

 

Equity Compensation plans approved by
   security holders

 

6,875,970

(1)

 

$9.31

 

2,402,485

(5)

Equity Compensation plans not approved by
   security holders
(2)

 

761,989

(3)

 

14.85

 

 

Total

 

7,637,959

 

 

$9.98

 

2,402,485

 

 

(1)
Consists of outstanding stock options and restricted stock units to purchase 6,875,970 awards pursuant to our 2008 Equity Incentive Plan, as amended (2008 Plan), our 2016 Plan, as amended (2016 Plan), and our 2023 Plan (2023 Plan).
(2)
Our Board has not established any specific number of shares that could be issued without stockholder approval.
(3)
Consists of an aggregate of 761,989 shares of our common stock under stock options issued as inducement grants as of December 31, 2023. These stock options are generally subject to the same terms and conditions as those awarded pursuant to the plans approved by our stockholders.
(4)
Restricted stock units are not included in the weighted-average exercise price calculation because there is no exercise price associated with stock units.
(5)
Consists of 2,274,390 available for issuance under the 2023 Plan and 128,095 shares available for issuance under our 2019 Employee Stock Purchase Plan, as amended.

EXECUTIVE OFFICER AND DIRECTOR COMPENSATION

Our named executive officers for the year ended December 31, 2023 are Dr. Jay Duker, our current President and Chief Executive Officer, Nancy Lurker, our former President and Chief Executive Officer and current Executive Vice Chair of the Board, George

24


 

Elston, our Executive Vice President and Chief Financial Officer, and Dr. Dario Paggiarino, our former Senior Vice President and Chief Medical Officer, who we collectively refer to as our Named Executive Officers.

Summary Compensation Table

The following table and footnotes provide information regarding the compensation of our Named Executive Officers for the year ended December 31, 2023 and the year ended December 31, 2022:

Executive Name and Principal
Position

 

Year

 

Salary
($)

 

 

Bonus
($)

 

 

Stock
Awards
($)
(3)

 

 

Option
Awards
($)
(4)

 

 

Non-Equity
Incentive Plan
Compensation
($)
(5)

 

 

All Other
Compensation
($)
(6)

 

 

Total
($)

 

 

Jay Duker

 

2023

 

 

614,064

 

 

 

47,225

 

(1)

 

658,859

 

 

 

961,793

 

 

 

605,877

 

 

 

27,328

 

 

 

2,915,146

 

 

President and Chief Executive Officer

 

2022

 

 

515,000

 

 

 

 

 

 

212,730

 

 

 

1,002,207

 

 

 

308,750

 

 

 

24,751

 

 

 

2,063,438

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Nancy Lurker

 

2023

 

 

570,025

 

 

 

49,242

 

(1)

 

1,038,477

 

 

 

1,479,628

 

 

 

574,486

 

 

 

25,527

 

 

 

3,737,385

 

 

Former President and Chief Executive Officer; Current Executive Vice Chair of the Board of Directors

 

2022

 

 

643,831

 

 

 

 

 

 

607,800

 

 

 

1,636,376

 

 

 

532,188

 

 

 

25,023

 

 

 

3,445,218

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

George Elston

 

2023

 

 

487,824

 

 

 

24,938

 

(1)

 

282,912

 

 

 

591,869

 

 

 

367,141

 

 

 

25,441

 

 

 

1,780,125

 

 

Executive Vice President and Chief Financial Officer

 

2022

 

 

469,062

 

 

 

 

 

 

177,275

 

 

 

477,277

 

 

 

253,089

 

 

 

23,941

 

 

 

1,400,644

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Dario Paggiarino(7)

 

2023

 

 

492,376

 

 

 

72,975

 

(2)

 

149,487

 

 

 

209,034

 

 

 

349,594

 

 

 

24,690

 

 

 

1,298,156

 

 

Former SVP, Chief Medical Officer

 

2022

 

 

472,344

 

 

 

 

 

 

177,275

 

 

 

477,277

 

 

 

255,450

 

 

 

23,974

 

 

 

1,406,320

 

 

 

(1)
The amount in this column represents a discretionary performance based bonus that was paid to the Named Executive Officer.
(2)
The amount in this column represents two separate discretionary performance based bonuses that were paid to Dr. Paggiarino in 2023.
(3)
These amounts represent the aggregate grant date fair value of restricted stock unit awards and performance stock unit awards granted during the applicable fiscal year period computed in accordance with FASB ASC Topic 718. For a more detailed discussion of the valuation model and assumptions used to calculate the fair value of each stock award, refer to Note 11 of the consolidated financial statements included in our Annual Report on Form 10-K for the year ended December 31, 2023 filed on March 8, 2024. The grant date fair value was measured at the date of Compensation Committee approval of stock awards to our Named Executive Officers.
(4)
These amounts represent the aggregate grant date fair value of option awards granted during the applicable fiscal year period computed in accordance with FASB ASC Topic 718. The grant date fair value of the option awards is estimated using the Black-Scholes option pricing model. For a more detailed discussion of the assumptions used to calculate the fair value of each option award, refer to Note 11 of the consolidated financial statements included in our Annual Report on Form 10-K for the year ended December 31, 2023 filed on March 8, 2024. The grant date fair value was measured at the date of Compensation Committee approval of option awards to our Named Executive Officers.
(5)
These amounts represent the amount of the annual performance bonus earned by the Named Executive Officer for calendar years 2023 and 2022, as applicable.
(6)
These amounts consist of 401(k) employer matching contributions and payment of group term life and long term disability insurance premiums.
(7)
Dr. Paggiarino's employment with the Company ended March 29, 2024.

Narrative Disclosure to Summary Compensation Table

Fiscal Year Base Salaries

In 2023, the initial annual base salary was $581,000 for Dr. Duker, $695,000 for Ms. Lurker, $492,561 for Mr. Elston, and $497,156 for Dr. Paggiarino. On July 10, 2023 Dr. Duker was appointed President and CEO with a base salary of $650,000 and Ms. Lurker was appointed Executive Vice Chair of the Board with an adjusted base salary of $455,000. For the fiscal year ending December 31, 2024, the Compensation Committee approved salary increases of 4% for each of our Named Executive Officers, with effect from April 1,

25


 

2024. The resulting annual base salaries are as follows: $676,000 for Dr. Duker, $473,200 for Ms. Lurker, $512,304 for Mr. Elston, and $517,088 for Dr. Paggiarino.

2023 Fiscal Year Non-Equity Incentive Plan Compensation and Discretionary Bonuses

Each of our executive officers is eligible to receive an annual performance bonus based on the achievement of corporate goals, as determined by our Board of Directors, and individual performance goals, as recommended by our Chief Executive Officer, for executives other than himself, and approved by the Compensation Committee. The performance bonus for our Chief Executive Officer and for our Executive Vice Chair is weighted 100% for achievement of our corporate goals, whereas the performance bonus for our other Named Executive Officers is weighted 75% for corporate goal achievement and 25% for individual goal achievement. The annual target bonus as a percentage of base salary was established at 60% for Dr. Duker (effective July 10, 2024 as CEO, 55% prior to such date), 45% for Ms. Lurker (effective July 10, 2024 as Executive Vice Chair, 65% prior to such date), and 45% for each of Mr. Elston and Dr. Paggiarino.

The corporate goals were pre-established by the Compensation Committee and the full Board of Directors for the year ended December 31, 2023. The corporate goals for 2023 consisted primarily of: (i) full enrollment and top line data release in the DAVIO 2 EYP-1901 Phase 2 clinical trial; (ii) full enrollment of the PAVIA EYP-1901 Phase 2 clinical trial; (iii) minimum cash target at year-end; and (iv) EYP-1901 clinical trial material readiness. The Compensation Committee approved a corporate performance score of 175% (the maximum permitted under the pre-established corporate goals) for the year ended December 31, 2023 on the basis that all of the 2023 corporate goals were achieved to the maximum amount permitted thereunder. The Compensation Committee also approved an additional 15% added to the corporate performance score for achievement of a minimum upfront payment in the closing of the out-license of the YUTIQ® franchise to Alimera Sciences Inc. Mr. Elston and Dr. Paggiarino were given individual performance scores of 138% and 100%, respectively. Actual bonus amounts earned with respect to the total 175% corporate goal achievement and the individual performance scores (as applicable) for the year ended December 31, 2023 are reflected in the “Non-Equity Incentive Plan Compensation” column and the additional 15% is reflected in the Bonus column of the Summary Compensation Table above.

2023 and 2024 Fiscal Year Equity Award Grants

 

On December 14, 2022, the Compensation Committee approved the following option grants to our Named Executive Officers: 124,755 options to Dr. Duker, 450,800 options to Ms. Lurker, 91,655 options to Mr. Elston, and 91,655 options to Dr. Paggiarino. The grants were made on January 6, 2023 with an exercise price of $3.26 per share, the closing price of the Company’s common stock on the date of grant, and the options will vest as to 25% of the total shares subject to the option on the one year anniversary of the grant date and then ratably over 36 months thereafter, provided that the executive maintains continuous employment with the Company during the vesting period. In addition, the Compensation Committee approved the following RSUs to be granted on January 6, 2023, to our Named Executive Officers: 62,380 RSUs to Dr. Duker, 225,400 RSUs to Ms. Lurker, 45,855 RSUs to Mr. Elston, and 45,855 RSUs to Dr. Paggiarino, all with pro rata annual vesting over three years.

 

On July 10, 2023, the Compensation Committee and the full Board of Directors approved the following equity grants to Dr. Duker and Ms. Lurker, in connection with amendments to their respective employment agreements and in conjunction with their appointments to the positions of President and CEO for Dr. Duker and Executive Vice Chair for Ms. Lurker, effective July 10, 2023: 100,000 options to Dr. Duker and 66,666 options to Ms. Lurker, each with an exercise price of $9.11 per share, the closing price of the Company’s common stock on the date of grant, and the options will vest as to 25% of the total shares subject to the option on the one year anniversary of the grant date and then ratably over 36 months thereafter, provided that the executive maintains continuous employment with the Company during the vesting period. 50,000 RSUs to Dr. Duker and 33,334 RSUs to Ms. Lurker, each with pro rata annual vesting over three years.

On December 13, 2023, the Compensation Committee approved the following option grants to our Named Executive Officers: 180,000 options to Dr. Duker, 77,000 options to Ms. Lurker, 90,000 options to Mr. Elston, and 42,000 options to Dr. Paggiarino. The grants were made on January 5, 2024 with an exercise price of $20.40 per share, the closing price of the Company’s common stock on the date of grant, and the options will vest as to 25% of the shares subject to the option after one year and then ratably over 36 months thereafter. In addition, on December 13, 2023, the Compensation Committee approved the grant of the following RSUs to be granted on January 5, 2024, to our Named Executive Officers: 90,000 RSUs to Dr. Duker, 38,000 RSUs to Ms. Lurker, 45,000 RSUs to Mr. Elston, and 21,000 RSUs to Dr. Paggiarino, all with pro rata annual vesting over three years.

401(k) Plan

We maintain a defined contribution 401(k) retirement plan (401(k) Plan) for all employees in the United States, including our Named Executive Officers. Employees are eligible to participate in the 401(k) Plan in the month following their date of hire. Under the terms

26


 

of the 401(k) Plan, participating employees may defer up to 100% of their pre-tax salary provided that such deferral is not in excess of the applicable statutory limits within any calendar year. The Company matches 100% of employee contributions up to a maximum of 6% of salary and bonus compensation, subject to annual Internal Revenue Service limits. Employee contributions and our company matching contributions to the 401(k) Plan vest immediately.

Employee Benefits and Perquisites

Our Named Executive Officers are eligible to participate in our health and welfare programs to the same extent as all full-time employees generally and are entitled to 20 days of annual paid time off in accordance with our vacation policy. We also provide our Named Executive Officers (NEO's) and other employees with group term life insurance and short and long-term disability (LTD) insurance at our expense. In addition to the regular LTD insurance, we offer Supplemental LTD insurance to our NEO's.

Employment Agreements

Jay Duker, who was appointed as our President and CEO on July 10, 2023 (he previously served as our Chief Operating Officer, and prior to that, served as Chief Strategic Scientific Officer), is employed under an employment agreement with us that provides for a base salary, a discretionary annual cash bonus based on the achievement of Company and individual performance goals, discretionary equity incentives, and severance payments as described further below under Additional Narrative Disclosure—Termination-Based Compensation.

Nancy Lurker, who was appointed our Executive Vice Chair of the Board of Directors on July 10, 2023 (she previously served as our President and Chief Executive Officer) is employed under an employment agreement with us that provides for a minimum base salary, a discretionary annual cash bonus based on the achievement of Company performance goals, discretionary equity incentives and severance payments as described further below under Additional Narrative Disclosure—Termination-Based Compensation.

 

George Elston, who became our Chief Financial Officer on November 14, 2019, is employed under an employment agreement that provides for a minimum base salary, a discretionary annual cash bonus based on the achievement of Company and individual performance goals, discretionary equity incentives, and severance payments as described further below under Additional Narrative Disclosure—Termination-Based Compensation.


Dario Paggiarino, our former Chief Medical Officer was hired on August 1, 2016, and was employed under an employment agreement with us that provided for a base salary, a discretionary annual cash bonus based on the achievement of the Company and individual performance goals, discretionary equity incentives, and severance payments as described further below under
Additional Narrative Disclosure—Termination-Based Compensation. Dr. Paggiarino's employment with the Company terminated involuntarily effective March 29, 2024.
 

 

 

27


 

Outstanding Equity Awards at 2023 Year End

The following table and footnotes provide information concerning outstanding equity awards for our Named Executive Officers as of December 31, 2023:

 

28


 

 

 

Option Awards

 

Stock Awards

 

 

Number of Securities
Underlying
Unexercised Options (#)

 

Option
Exercise
Price

 

 

Option
Expiration

 

Number of
shares or
units of
stock that
have not vested

 

Market value
of shares or
units of stock
that have not
vested

 

 

Equity
incentive
plan awards:
number of
unearned
shares, units
or other rights
that have not vested

 

Equity
incentive
plan awards:
market or
payout value
of unearned
shares, units
or other rights
that have not
yet vested

Name

 

Exercisable

 

 

Unexercisable

 

 

 

($)

 

 

Date

 

(#)

 

($)(9)

 

 

(#)

 

($)

Jay Duker

 

 

4,000

 

 

 

 

 

 

 

31.7000

 

 

09/26/26

 

 

 

 

 

 

 

 

 

 

 

 

 

 

2,666

 

 

 

 

 

 

 

19.5000

 

 

06/21/28

 

 

 

 

 

 

 

 

 

 

 

 

 

 

4,000

 

 

 

 

 

 

 

26.5000

 

 

02/21/29

 

 

 

 

 

 

 

 

 

 

 

 

 

 

3,350

 

 

 

 

 

 

 

12.9000

 

 

02/28/30

 

 

 

 

 

 

 

 

 

 

 

 

 

 

21,357

 

 

 

3,643

 

(1)

 

 

7.2000

 

 

07/13/30

 

 

 

 

 

 

 

 

 

 

 

 

 

 

42,712

 

 

 

17,588

 

(1)

 

 

13.1300

 

 

02/09/31

 

 

 

 

 

 

 

 

 

 

 

 

 

 

124,847

 

 

 

114,853

 

(1) (10)

 

 

11.4700

 

 

11/01/31

 

 

 

 

 

 

 

 

 

 

 

 

 

 

38,958

 

 

 

46,042

 

(1)

 

 

10.1300

 

 

02/09/32

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

36,731

 

 

 

28,569

 

(1)

 

 

9.4500

 

 

09/06/32

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

124,755

 

(1)

 

 

3.2600

 

 

01/05/33

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

100,000

 

(1)

 

 

9.1100

 

 

07/10/33

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

131,347

 

(5)

 

 

3,035,429

 

 

 

 

 

 

Nancy Lurker

 

 

85,000

 

 

 

 

(11)

 

 

36.3000

 

 

09/15/26

 

 

 

 

 

 

 

 

 

 

 

 

 

 

24,000

 

 

 

 

(11)

 

 

17.7000

 

 

06/27/27

 

 

 

 

 

 

 

 

 

 

 

 

 

 

54,000

 

 

 

 

(11)

 

 

20.4000

 

 

06/14/28

 

 

 

 

 

 

 

 

 

 

 

 

 

 

93,000

 

 

 

 

(11)

 

 

26.5000

 

 

02/21/29

 

 

 

 

 

 

 

 

 

 

 

 

 

 

71,684

 

 

 

3,116

 

(2) (11)

 

 

12.9000

 

 

02/28/30

 

 

 

 

 

 

 

 

 

 

 

 

 

 

151,370

 

 

 

62,330

 

(2) (11)

 

 

13.1300

 

 

02/09/31

 

 

 

 

 

 

 

 

 

 

 

 

 

 

110,000

 

 

 

130,000

 

(2) (11)

 

 

10.1300

 

 

02/09/32

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

450,800

 

(2)

 

 

3.2600

 

 

01/05/33

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

66,666

 

(2)

 

 

9.1100

 

 

07/10/33

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

316,268

 

(6)

 

 

7,308,953

 

 

 

 

 

 

George Elston

 

 

74,500

 

 

 

 

 

 

 

14.2000

 

 

11/14/29

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

10,579

 

 

 

458

 

(3)

 

 

12.9000

 

 

02/28/30

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

42,712

 

 

 

17,588

 

(3)

 

 

13.1300

 

 

02/09/31

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

32,083

 

 

 

37,917

 

(3)

 

 

10.1300

 

 

02/09/32

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

91,655

 

(3)

 

 

3.2600

 

 

01/05/33

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

45,000

 

(3)

 

 

5.9300

 

 

05/24/33

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

30,000

 

(3)

 

 

8.2300

 

 

10/15/33

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

84,989

 

(7)

 

 

1,964,096

 

 

 

 

 

 

Dario Paggiarino

 

 

23,000

 

 

 

 

 

 

 

39.3000

 

 

08/01/26

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

6,000

 

 

 

 

 

 

 

17.7000

 

 

06/27/27

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

17,050

 

 

 

 

 

 

 

20.4000

 

 

06/14/28

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

37,000

 

 

 

 

 

 

 

26.5000

 

 

02/21/29

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

23,599

 

 

 

1,026

 

(4)

 

 

12.9000

 

 

02/28/30

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

42,712

 

 

 

17,588

 

(4)

 

 

13.1300

 

 

02/09/31

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

37,917

 

(4)

 

 

10.1300

 

 

02/09/32

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

91,655

 

(4)

 

 

3.2600

 

 

01/05/33

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

62,489

 

(8)

 

 

1,444,121

 

 

 

 

 

 

 

(1)
Dr. Duker’s unexercisable options vest and become exercisable as follows: 3,643 ratably monthly through July 13, 2024, 17,588 ratably monthly through February 9, 2025, 114,853 ratably monthly through November 1, 2025, 46,042 ratably monthly through February 9, 2026, 28,569 ratably monthly through September 7, 2025, 124,755 as to 25% at the one year anniversary of the

29


 

grant date and the remainder ratably monthly through January 6, 2027, and 100,000 as to 25% at the one year anniversary of the grant date and the remainder ratably monthly through July 10, 2027.
(2)
Ms. Lurker’s unexercisable options vest and become exercisable as follows: 3,116 ratably monthly through February 28, 2024, 62,330 ratably monthly through February 9, 2025, 130,000 ratably monthly through February 9, 2026, 450,800 as to 25% at the one year anniversary of the grant date and the remainder ratably monthly through January 6, 2027, and 66,666 as to 25% at the one year anniversary of the grant date and the remainder ratably monthly through July 10, 2027.
(3)
Mr. Elston’s unexercisable options vest and become exercisable as follows: 458 ratably monthly through February 28, 2024, 17,588 ratably monthly through February 9, 2025, 37,917 ratably monthly through February 9, 2026, 91,655 as to 25% at the one year anniversary of the grant date and the remainder ratably monthly through January 6, 2027, 45,000 as to 25% at the one year anniversary of the grant date and the remainder ratably monthly through May 25, 2027, and 30,000 as to 25% at the one year anniversary of the grant date and the remainder ratably monthly through October 16, 2027.
(4)
Dr. Paggiarino’s unexercisable options vest and become exercisable as follows: 1,026 ratably monthly through February 28, 2024, 17,588 ratably monthly through February 9, 2025, 37,917 ratably monthly through February 9, 2026, and 91,655 as to 25% at the one year anniversary of the grant date and the remainder ratably monthly through January 6, 2027. Effective March 29, 2024, 115,939 options vested per the terms of Dr. Paggiarino's separation agreement.
(5)
Dr. Duker’s restricted stock units vest as follows: 4,967 is on installment on February 9, 2024, 14,000 in two ratable annual installments commencing February 9, 2024, 62,380 in three ratable annual installments commencing January 6, 2024, and 50,000 in three ratable annual installments commencing July 10, 2024.
(6)
Ms. Lurker’s restricted stock units vest as follows: 17,534 in one installment commencing on February 9, 2024 and 40,000 in two ratable annual installments commencing February 9, 2024, 225,400 in three ratable annual installments commencing January 6, 2024, and 33,334 in three ratable annual installments commencing July 10, 2024.
(7)
Mr. Elston's restricted stock units vest as follows: 4,967 in one installment commencing on February 9, 2024 and 11,667 in two ratable annual installments commencing February 9, 2024, 22,500 in three ratable annual installments commencing May 25, 2024, and 45,855 in three ratable annual installments commencing January 6, 2024.
(8)
Dr. Paggiarino's restricted stock units vest as follows: 4,967 in one installment commencing February 9, 2024, 11,667 in two ratable annual installments commencing February 9, 2024, and 45,855 in three ratable annual installments commencing January 6, 2024. Effective March 29, 2024, 50,404 RSU's vested per the terms of Dr. Paggiarino's separation agreement.
(9)
The market price of unvested and unearned stock awards is calculated based on the closing price of our common stock at December 31, 2023 of $23.11, as reported on the Nasdaq Global Market.
(10)
Due to an administrative error, the 2022 Annual Meeting Proxy Statement incorrectly reported that Dr. Duker received an option grant of 305,000 shares of our common stock in conjunction with his appointment as our Chief Operating Officer effective November 1, 2021, when it should have been reported as 239,700 shares of our common stock. The table has been updated to correct this administrative error.
(11)
As of December 31, 2023, 587,496 of the vested options have been gifted to an irrevocable family trust of which Ms. Lurker’s spouse is trustee and of which Ms. Lurker’s immediate family members are the sole beneficiaries.

Additional Narrative Disclosure

Stock Ownership Guidelines

We have adopted stock ownership guidelines for our executive officers. These guidelines were established to further align the interests of our executive officers with those of our stockholders and to promote our commitment to sound corporate governance practices. In 2021, upon the guidance of Aon, the ownership guidelines for our executive officers were updated and are listed below:

 

Multiple of Base Salary

Chief Executive Officer

 

3x

Each Other Executive Officer covered by the Guidelines

 

1x

 

Owned shares as well as unvested time-based restricted shares are counted towards meeting the guidelines.

All executive officers have five years from the date of their appointment as a Section 16 officer (or the date on which the Compensation Committee adopts new guidelines) to meet these guidelines, and their stock ownership is reviewed annually by the Compensation Committee. For Dr. Duker the compliance deadline is November 1, 2026 and for Ms. Lurker and Mr. Elston the compliance deadline is August 1, 2026. As of April 23, 2024, all of the listed Named Executive Officers were in compliance with these guidelines.

Clawback Policy

 

30


 

We have a compensation recoupment, or clawback, policy, which we adopted in October 2023 to comply with Nasdaq listing standards implementing Exchange Act Rule 10D-1. The clawback policy includes mandatory recoupment of excess incentive-based compensation received by a covered executive (including the Named Executive Officers) on or after October 2, 2023 in the event of a restatement of the Company’s financial statements due to material non-compliance with any financial reporting requirement under federal securities laws, as required by Exchange Act Rule 10D-1. The clawback policy replaced our former clawback policy in its entirety.

Termination-Based Compensation

Jay Duker

 

Effective July 10, 2023, the Board appointed Dr. Duker, as the Company's President and Chief Executive Officer, effective as of July 10, 2023. In connection with Dr. Duker’s appointment to President and Chief Executive Officer, the Company and Dr. Duker entered into an amendment (the Duker Amendment) to that certain Amended and Restated Employment Agreement, effective as of November 1, 2021, as amended by that certain First Amendment to Employment Letter Agreement, effective as of January 3, 2023, by and between the Company and Dr. Duker (as amended, the Duker Employment Agreement).

If Dr. Duker’s employment is terminated by the Company without Cause or by Dr. Duker for Good Cause (as such terms are defined in the Duker Employment Agreement), Dr. Duker will be entitled to (a) his base salary for the period of 12 months from the date of termination; (b) 100% of his target bonus for the calendar year in which his employment terminates, pro-rated through the date of termination; (c) 100% of his target bonus, in each case of (a), (b) and (c), payable in equal installments during the period of base salary continuation payable in clause (a); and (d) reimbursements equal to the portion of the monthly health premiums paid by the Company on Dr. Duker’s behalf and that of his eligible dependents immediately preceding the date that Dr. Duker’s employment terminates until the earlier of (i) the last day of the period of base salary continuation under clause (a) and (ii) the date that Dr. Duker and his eligible dependents become ineligible for COBRA coverage. In addition, any unvested equity awards held by Dr. Duker as of immediately prior to his termination of employment that would have vested as of the first anniversary of the date of his termination of employment had he remained in continuous employment with the Company or any subsidiary through such first anniversary will vest upon Dr. Duker’s termination of employment and any such equity awards that are subject to exercise shall remain exercisable until the earlier of three (3) months following the date of Dr. Duker’s termination of employment and the last day of the option term.

In the event Dr. Duker’s employment is terminated by the Company without Cause or by Dr. Duker for Good Cause within 60 days prior to, or within 18 months following a "Change of Control" (as such term is defined in the Duker Employment Agreement), the Company will pay Dr. Duker (i) his base salary for 18 months from the date of termination, payable in a lump sum; (ii) 100% of his target bonus for the calendar year in which his employment terminates, pro-rated through the date of termination payable in a lump sum; (iii) 150% of his target bonus payable in a lump sum; and (iv) reimbursements equal to the portion of the monthly health premiums paid by the Company on Dr. Duker’s behalf and that of his eligible dependents immediately preceding the date that Dr. Duker’s employment terminates until the earlier of (A) the last day of the period of base salary continuation under clause (i) and (B) the date that Dr. Duker and his eligible dependents become ineligible for COBRA coverage. In addition, all of Dr. Duker’s then-outstanding equity awards will immediately accelerate and vest in full upon such termination of employment (or, if later, upon the occurrence of the Change of Control) and any such equity awards that are subject to exercise shall remain exercisable until the earlier of the first anniversary of the date of Dr. Duker’s termination (or three (3) months following the date of his employment termination in the case of any incentive stock options) and the last day of the option term.

In addition to the payments set forth in the preceding paragraphs, upon the termination of Dr. Duker’s employment for any reason, Dr. Duker will be entitled to receive any earned or accrued amounts and vested benefits that remain unpaid as of the date of his termination of employment.

Dr. Duker’s right to receive the severance payments and benefits described above under his employment agreement is conditioned upon his execution and non-revocation of a separation agreement containing a general release of claims. Dr. Duker’s employment agreement contains certain restrictive covenants, including non-disclosure of confidential information, assignment of rights to intellectual property, a non-competition covenant that runs for 12 months following his termination of employment for any reason, a non-solicitation covenant with respect to certain of our customers, vendors, suppliers, and business partners that runs for 12 months following his termination of employment for any reason, and a non-solicitation covenant with respect to our employees and independent contractors that runs for 12 months following his termination of employment.

Nancy Lurker

 

Effective as of July 10, 2023, Ms. Lurker transitioned from her role as Chief Executive Officer of the Company to Executive Vice Chair of Board of Directors. Ms. Lurker continues to serve as a member of the Board.

31


 

 

In connection with Ms. Lurker’s transition, the Company and Ms. Lurker entered into an amendment (the Lurker Amendment to that certain Employment Letter Agreement, dated September 15, 2016, as amended by that certain First Amendment to Employment Letter Agreement, effective as of January 3, 2023, by and between the Company and Ms. Lurker (as amended, the Lurker Employment Agreement). The Lurker Amendment provides that Ms. Lurker will serve as Executive Vice Chair for one year from the Lurker Transition Date (the Initial Term), subject to an extension of up to six months upon the expiration of the Initial Term by the Board at its sole discretion (if exercised by the Board, the Extension Term and together with the Initial Term, the Term). Under the Lurker Amendment, expiration of the Term will not constitute a termination of employment by the Company without Cause (as defined in the Lurker Employment Agreement) or constitute grounds for Ms. Lurker to terminate her employment for Good Cause (as defined in the Lurker Employment Agreement).

If Ms. Lurker’s employment is terminated by the Company without Cause or by Ms. Lurker for Good Cause (as such terms are defined in the Lurker Employment Agreement), Ms. Lurker will be entitled to (a) her base salary for the period of 18 months from the date of termination; (b) 100% of her target bonus for the calendar year in which her employment terminates, pro-rated through the date of termination; (c) 150% of her target bonus, in each case of (a), (b) and (c), payable in equal installments during the period of base salary continuation payable in clause (a); and (d) reimbursements equal to the portion of the monthly health premiums paid by the Company on Ms. Lurker’s behalf and that of her eligible dependents immediately preceding the date that Ms. Lurker’s employment terminates until the earlier of (A) the last day of the period of base salary continuation under clause (a) and (B) the date that Ms. Lurker and her eligible dependents become ineligible for COBRA coverage. In addition, any unvested options to purchase common stock of the Company held by Ms. Lurker as of immediately prior to her termination of employment that would have vested as of the eighteen (18) month anniversary of the date of her termination of employment had she remained in continuous employment with the Company or any subsidiary through such eighteen (18) month anniversary will vest upon Ms. Lurker’s termination of employment and shall remain exercisable until the earlier of three (3) months following the date of Ms. Lurker’s termination of employment and the last day of the option term.

In the event Ms. Lurker’s employment is terminated by the Company without Cause or by Ms. Lurker for Good Cause within 60 days prior to, or within 18 months following a "Change of Control" (as such term is defined in the Lurker Employment Agreement), the Company will pay Ms. Lurker (i) her base salary for 24 months from the date of termination, payable in a lump sum; (ii) 100% of her target bonus for the calendar year in which her employment terminates, pro-rated through the date of termination payable in a lump sum; (iii) 200% of her target bonus payable in a lump sum; and (iv) reimbursements equal to the portion of the monthly health premiums paid by the Company on Ms. Lurker’s behalf and that of her eligible dependents immediately preceding the date that Ms. Lurker’s employment terminates until the earlier of (A) the end of the twenty-four (24) month period immediately following the date of termination and (B) the date that Ms. Lurker and her eligible dependents become ineligible for COBRA coverage. In addition, all of Ms. Lurker’s then-outstanding equity awards will immediately accelerate and vest in full upon such termination of employment (or, if later, upon the occurrence of the Change of Control) and any such equity awards that are subject to exercise shall remain exercisable until the earlier of the first anniversary of the date of Ms. Lurker’s termination (or three (3) months following the date of her employment termination in the case of any incentive stock options) and the last day of the option term.

In addition to the payments set forth in the preceding paragraphs, upon the termination of Ms. Lurker’s employment for any reason, Ms. Lurker will be entitled to receive any earned or accrued amounts and vested benefits that remain unpaid as of the date of her termination of employment.

Ms. Lurker’s right to receive the severance payments and benefits described above under her employment agreement is conditioned upon her execution and non-revocation of a separation agreement containing a general release of claims. Ms. Lurker’s employment agreement contains certain restrictive covenants, including non-disclosure of confidential information, assignment of rights to intellectual property, a non-competition covenant that runs for 12 months following her termination of employment for any reason, a non-solicitation covenant with respect to certain of our customers, vendors, suppliers, and business partners that runs for 12 months following her termination of employment for any reason, and a non-solicitation covenant with respect to our employees and independent contractors that runs for 12 months following her termination of employment.

George Elston

If Mr. Elston’s employment is terminated by the Company without Cause or by Mr. Elston for Good Cause (as such terms are defined in the A&R Elston Employment Agreement), Mr. Elston will be entitled to (a) his base salary for the period of 12 months from the date of termination; (b) 100% of his target bonus for the calendar year in which his employment terminates, pro-rated through the date of termination; (c) 100% of his target bonus, in each case of (a), (b), and (c), payable in equal installments during the period of base salary continuation payable in clause (a); and (d) reimbursements equal to the portion of the monthly health premiums paid by the Company on Mr. Elston’s behalf and that of his eligible dependents immediately preceding the date that Mr. Elston’s employment terminates until the earlier of (i) the last day of the period of base salary continuation under clause (a) and (ii) the date that Mr. Elston

32


 

and his eligible dependents become ineligible for COBRA coverage. In addition, any unvested equity awards held by Mr. Elston as of immediately prior to his termination of employment that would have vested as of the first anniversary of the date of his termination of employment had he remained in continuous employment with the Company or any subsidiary through such first anniversary will vest upon Mr. Elston’s termination of employment and any such equity awards that are subject to exercise shall remain exercisable until the earlier of three (3) months following the date of Mr. Elston’s termination of employment and the last day of the option term.

In the event Mr. Elston’s employment is terminated by the Company without Cause or by Mr. Elston for Good Cause within 60 days prior to, or within 18 months following a "Change of Control" (as such term is defined in the Elston Employment Agreement), the Company will pay Mr. Elston (i) his base salary for 18 months from the date of termination, payable in a lump sum; (ii) 100% of his target bonus for the calendar year in which his employment terminates, pro-rated through the date of termination payable in a lump sum; (iii) 150% of his target bonus payable in a lump sum; and (iv) reimbursements equal to the portion of the monthly health premiums paid by the Company on Mr. Elston’s behalf and that of his eligible dependents immediately preceding the date that Mr. Elston’s employment terminates until the earlier of (A) the end of the eighteen (18) month period immediately following the date of termination and (B) the date that Mr. Elston and his eligible dependents become ineligible for COBRA coverage. In addition, all of Mr. Elston’s then-outstanding equity awards will immediately accelerate and vest in full upon such termination of employment (or, if later, upon the occurrence of the Change of Control) and any such equity awards that are subject to exercise shall remain exercisable until the earlier of three (3) months following the date of his employment termination and the last day of the option term.

In addition to the payments set forth in the preceding paragraphs, upon the termination of Mr. Elston's employment for any reason, Mr. Elston will be entitled to receive any earned or accrued amounts and vested benefits that remain unpaid as of the date of his termination of employment.

Mr. Elston’s right to receive the severance payments and benefits described above under his employment agreement is conditioned upon his execution and non-revocation of a separation agreement containing a general release of claims. Mr. Elston's employment agreement contains certain restrictive covenants, including non-disclosure of confidential information, assignment of rights to intellectual property, a non-competition covenant that runs for 12 months following his termination of employment for any reason, a non-solicitation covenant with respect to certain of our customers, vendors, suppliers, and business partners that runs for 12 months following his termination of employment for any reason, and a non-solicitation covenant with respect to our employees and independent contractors that runs for 12 months following his termination of employment.

Dario Paggiarino

Dr. Paggiarino's employment with the Company terminated involuntarily effective March 29, 2024 (Separation Date). Pursuant to the Severance and General Release Agreement entered into between Dr. Paggiarino and the Company, Dr. Paggiarino received severance pay in the amount of $807,950, which included (a) his base salary for the period of 12 months from the Separation Date ($517,088), plus (b) 100% of his target bonus for the 2024 calendar year ($232,689.60), plus (c) 100% of his target bonus for the 2024 calendar year, pro-rated through the Separation Date ($58,172.40). The severance payments will be payable in equal twice-monthly installments during the 12-month period of base salary continuation.

 

The vesting of Dr. Paggiarino’s unvested stock options (the Accelerated Stock Options) and unvested restricted stock units (the Accelerated RSUs) accelerated by two years as of the Separation Date, and such Accelerated Stock Options and Accelerated RSUs were deemed fully vested on the Separation Date. Further, Dr. Paggiarino's previously vested stock options as of the Separation Date and the Accelerated Stock Options will remain outstanding and exercisable until the date that is 12 months following the Separation Date. Dr. Paggiarino held 211,978 options exercisable and 50,404 vested RSUs, including Accelerated Stock Options and Accelerated RSUs, as of the Separation Date

 

Dr. Paggiarino is entitled to receive reimbursements equal to the portion of the monthly health premiums paid by the Company on Dr. Paggiarino’s behalf and that of his eligible dependents immediately preceding the date of termination until the earlier of (i) the last day of the period of base salary continuation and (ii) the date that Dr. Paggiarino and his eligible dependents become ineligible for COBRA coverage.

 

Dr. Paggiarino’s right to receive the severance payments and benefits described above were conditioned upon his agreement to a general release of claims. Dr. Paggiarino's employment agreement contains certain restrictive covenants, including non-disclosure of confidential information, assignment of rights to intellectual property, a non-competition covenant that runs for 12 months following his termination of employment, a non-solicitation covenant with respect to certain of our customers, vendors, suppliers, and business partners that runs for 12 months following his termination of employment, and a non-solicitation covenant with respect to our employees and independent contractors that runs for 12 months following his termination of employment.

33


 

DIRECTOR COMPENSATION

Compensation Summary

The following table and footnotes provide information regarding the compensation paid to our non-executive directors for the year ended December 31, 2023:

 

Name

 

Fees Earned
or Paid in
Cash ($)

 

 

Option
Awards ($)
(1)(2)

 

 

Stock
Awards ($)
(1)(2)

 

 

All Other
Compensation ($)

 

 

Total ($)

 

Göran Ando

 

 

117,000

 

 

 

97,784

 

 

 

 

 

 

 

 

 

214,784

 

John Landis(3)

 

 

67,500

 

 

 

94,171

 

 

 

 

 

 

 

 

 

161,671

 

David Guyer

 

 

86,500

 

 

 

94,171

 

 

 

 

 

 

 

 

 

180,671

 

Wendy DiCicco

 

 

77,500

 

 

 

94,171

 

 

 

 

 

 

 

 

 

171,671

 

Ye Liu(4)

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Anthony P. Adamis

 

 

52,500

 

 

 

94,171

 

 

 

 

 

 

 

 

 

146,671

 

Karen Zaderej

 

 

55,000

 

 

 

94,171

 

 

 

 

 

 

 

 

 

149,171

 

Stuart Duty

 

 

9,932

 

 

 

371,164

 

 

 

 

 

 

 

 

 

381,096

 

 

(1)
The amounts in these columns reflect the grant date fair value as determined in accordance with FASB ASC Topic 718. The underlying valuation assumptions for equity awards are further disclosed in Note 11 of the audited financial statements filed with our Annual Report on Form 10-K for the year ended December 31, 2023.
(2)
The following table shows the aggregate number of outstanding shares underlying outstanding options and restricted stock units held by our non-executive directors as of December 31, 2023:

 

Name

 

Outstanding
Option Awards

 

 

Outstanding
Stock Awards

 

Göran Ando

 

 

82,950

 

 

 

 

John Landis

 

 

76,450

 

 

 

 

David Guyer

 

 

72,450

 

 

 

 

Wendy DiCicco

 

 

72,450